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membrane and thus soluble/secreted form of Jagged1 is
able to promote not only cell growth but also the forma-
tion of collagen Type I-dependent chord-like structures
and in the presence of FGF regulates cell transformation.
The ability of secreted/soluble Jagged1 to promote
matrix-dependent chord formation is dependent on the
intracellular signaling function of the Src gene family since
a dominant-negative Src construct inhibits a matrix-
dependent chord formation but not the induction of FGF-
dependent cell transformation. These data argue that
signaling mediated by Jagged1 may be involved not only
in the regulation of FGF-dependent cell growth but may
also be involved in the regulation of the chord formation,
a process requisite for the formation of luminal structures.
CYTOPLASMIC SIGNALING AND THE
CYTOSKELETON
Michael T. Crow, PhD
Laboratory of Cardiovascular Science
NIA-NIH
Cytoplasmic signaling plays a critical role in linking cell
surface receptor activation to various intracellular targets.
One such target that is critically important for proper cell
function is the cytoskeleton. The cytoskeleton provides the
structural framework for the cell, dictating its shape, move-
ment, and polarity, and modulating its interaction with
other cells and the extracellular matrix. Such interactions
are necessary for maintaining proper tissue differentiation,
organization, and function. Extracellular matrix interac-
tions affect cytoskeletal organization and, therefore, cellu-
lar behavior and function, through integrin-dependent
cytoplasmic signaling. This pathway from integrin-matrix
interactions through cytoplasmic signaling to cytoskeletal
alterations, however, is not a one-way street. Reciprocal
interactions occur at each stage of the signaling cascade, with
integrins both initiating cytoplasmic signaling (“outside-in”
signaling) and serving as targets of such signaling (“inside-
out” signaling). Outside-in and inside-out signaling of inte-
grins forms the basis for crosstalk, which is necessary to
coordinate the functions of the many integrins expressed in
a single cell. These include phagocytosis, cell proliferation,
platelet activation, and migration. Cytoplasmic signaling
pathways necessary for such signaling related to vascular cell
function are discussed in the first half of the presentation
(“Cytoplasmic signaling from integrins to the cytoskeleton
and back”).
Reciprocity also occurs at the level of cytoplasmic sig-
naling and cytoskeletal organization, with the cytoskeleton
RECEPTOR-MEDIATED SIGNALING BY
GROWTH FACTORS, CYTOKINES, AND CELL
FATE DETERMINANTS IN THE REGULATION
OF ENDOTHELIAL CELL FUNCTION
T. Maciag*
Scarborough, Me
Endothelial cell growth, migration, and differentiation
are regulated by signaling pathways established by
polypeptide growth factors, cytokines, and cell fate deter-
minants, and this laboratory has studied in some detail the
ability of FGF1, IL1α, and Jagged1 as mediators of these
events. The ability of cells to respond to FGF1 as a chemo-
tactic factor requires only intermittent contact (4 hours
minimum), yet the ability of FGF1 to induce DNA syn-
thesis requires its presence in the extracellular compart-
ment during the entire G1 phase of the cell cycle (12-14
hours minimum). Additional studies have demonstrated
that the signaling pathway utilized by FGFR1 to regulate
migration involves the function of members of the Src
gene family and its substrate, cortactin, while the
Ras/MAPK pathway is utilized to signal cell proliferation.
An additional regulatory event involves the ability of the
FGF prototypes to access the extracellular compartment
since they do not contain classical signal peptide sequences
for entry into the ER-Golgi apparatus for secretion. This
structural feature is also shared by the signal peptide-less
members of the proinflammatory IL1 gene family, which
are well described as FGF antagonists. Interestingly, (i)
both FGF1 and IL1α are released in response to stress, (ii)
the FGF1 and IL1α release pathways involve the function
of cell-associated proteases, and (iii) the precursor domain
of IL1α is able to function as an inhibitor of FGF1 release
in response to stress. While current evidence suggests that
the release of FGF1 involves the function of members of
the synaptotagmin and S100 gene families as well as phos-
phatidylserine flipping from the inner to outer plasma
membrane leaflet, the role of these factors in the stress-
induced IL1α release pathway has not been established.
Although the agonist/antagonist roles of FGF and IL1 are
well established, there is another ligand-receptor system
that may also function in coordination with these signals.
This pathway involves the function of the cell fate trans-
membrane determinant, Jagged1 to signal through its
transmembrane receptor, Notch. Interestingly, a nontrans-
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serving as both target and modulator of cytoplasmic signal-
ing. The importance of the cytoskeleton in modulating
cytoplasmic signaling is highlighted by recent studies show-
ing that apoptotic signaling in endothelial cells is dependent
on cytoskeletal organization and studies showing the bene-
ficial effects of 3-hydroxy-5-methylglutaryl(HMG)-CoA
reductase inhibitors (“statins”), exceeds their lipid-lowering
abilities, and is related to their ability to block Rho-depen-
dent changes in cytoskeletal organization. These topics are
discussed in the second half of the presentation
(Cytoskeletal-dependent cytoplasmic signaling). 
Cytoplasmic signaling from integrins to the cytoskele-
ton and back 
In response to PDGF released by activated platelets
adhering to the denuded surface of injured blood vessels,
vascular smooth muscle cells (VSMCs) migrate from their
normal residence in the medial cell layer of vessels into the
intimal cell layer. There, in their de-differentiated state,
they play a significant role in the eventual demise of the
vessel structure and function. Similar migratory events
underlie the pathogenesis of atherosclerosis, hypertension,
and aging. We previously showed the multifunctional pro-
tein kinase, calcium/calmodulin-dependent protein kinase
II (CamKII), is a key intracellular signaling event that reg-
ulates VSMC movement in parallel with the regulation of
matrix degradation. These studies showed that activation
of CamKII is a central control point for VSMC migration,
integrating signals from growth factors and the differenti-
ation status of the cells. Cell movement requires activated
CamKII and constitutively active mutants of CamKII
override many of the conditions that, in normal vessels, act
to suppress VSMC movement.
CamKII also plays an important role in extracellular
matrix signaling through the integrin, αvβ3. Expression of
αvβ3 is induced in VSMCs in response to vessel injury. β3
Integrin antagonists that were originally developed to tar-
get thrombotic events associated with balloon angioplasty
and initiated by αIIbβ3, show prolonged effects on sup-
pressing restenosis that have been attributed to inhibition
of αvβ3 on VSMCs. Ligand-engaged αvβ3 more than
doubles the rate of migration and is dependent on activa-
tion of CamKII.1 Interestingly, VSMCs from older ani-
mals seem to be capable of bypassing this ergulation by
αvβ3 despite expressing approximately equivalent levels of
the integrin.2
Outside-in signaling through the αvβ3 integrin to
CamKII is also involved in integrin crosstalk with the
α5β1(fibronectin) receptor. αvβ3 Inhibits α5β1-depen-
dent functions. This inhibition is mediated through
CamKII activation since: (a) αvβ3 stimulates CamKII
activity; (b) crosstalk is inhibited and high affinity α5β1
functions restored when CamKII activity is inhibited; and
(c) crosstalk is restored, even in the absence of αvβ3
expression, when a constitutively activated mutant of
CamKII is expressed in the cell.3
Transfection of constitutively activated CamKII into
vascular cells shifts the subcellular distribution of cytoskele-
JOURNAL OF VASCULAR SURGERY
Volume 33, Number 6 Lifeline Research Meeting Abstracts 1287
tal actin away from stress fiber formation to cortical actin
deposition. Possible targets for CamKII phosphorylation
are consistent with such a shift. One is myosin light chain
kinase (MLCK), the enzyme responsible for phosphoryla-
tion of the regulatory myosin light chains (MLC), which in
nonmuscle and smooth muscle triggers assembly of stress
fibers. CamKII phosphorylates MLCK, inhibiting its activ-
ity. That this is potentially an important target of CamKII
signaling is suggested by the fact that inhibitors of MLCK
reverse many of the effects of CamKII inhibition. Another
potentially interesting target for CamKII is Tiam-1, a Rac
guanine-nucleotide exchange factor. CamKII phosphory-
lates Tiam-1, resulting in increased Rac activity. Rac pro-
motes cortical actin organization and, through its binding
to p21rac-associated kinase or PAK, also inhibits MLCK
activity. A truncated Tiam-1 expression vector lacking the
dbl homology (DH) domain functions as a dominant neg-
ative mutant. When transfected into VSMCs, PDGF-stim-
ulated Rac activation, cortical actin deposition, and
migration. The blockade could be bypassed by constitu-
tively activated rac1, but not CamKII, indicating that it
occurs downstream of CamKII. 
Cytoskeletal-dependent cytoplasmic signaling
In addition to its role as the major structural frame-
work for the cell, the cytoskeleton is also the scaffold on
which much of cytoplasmic signaling takes place.4,5 As
such, its role in modulating cytoplasmic signaling is
increasingly recognized as an important factor in cellular
signaling, in general, and vascular pathophysiology, in par-
ticular. Although three microfilamentous systems (actin,
tubulin, and vimentin) comprise the cytoskeleton, the
focus here is primarily on the actin cytoskeleton. The
other microfilaments, however, have important effects on
cytoplasmic signaling, either directly or indirectly through
their ability to alter the actin cytoskeleton.
The importance of the cytoskeleton is illustrated by the
effect that changes in the cytoskeletal organization have on
the response of endothelial cells (ECs) to inflammatory
cytokines, such as TNF, which causes loss of cell barrier
function (ie, increased intercellular permeability) and apop-
tosis. One of the earliest responses of the ECs to TNF is
the formation of myosin-based stress fibers throughout the
cell. These events precede the changes in barrier function
and apoptosis. Inhibitors of MLCK or Rho-kinase
(ROCK) both block MLC phosphorylation, an event nec-
essary for myosin assembly into stress fibers. Both
inhibitors also significantly attenuate apoptosis caused by
TNF.6 This occurs despite the fact that the permeability
changes induced by TNF remained unaltered, suggesting
that receptor levels and early signaling events are not
affected by the inhibitors. One possibility is that effect of
the MLCK inhibitors is unrelated to the changes in
cytoskeletal organization and, therefore, MLCK inhibition
per se. Thus, endothelial cells express a family of related
kinases linked to cell death known as DAP (death-associated
protein) Kinases. These also are calcium/calmodulin sensi-
tive enzymes that can phosphorylate MLC, although it is
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not clear if MLC is the actual cellular target responsible for
death-inducing properties. This scenario would require
that the substrate for DAPK also be a target for Rho-
kinase, since inhibition of Rho or Rho-kinase is as effective
as MLCK inhibition in attenuating apoptosis. 
Another attractive possibility is suggested by a series of
experiments exploring the effects of the HMG-CoA reduc-
tase inhibitors, known collectively as “statins,” on cell sig-
naling and cell function. These inhibitors were designed to
originally be used as lipid-lowering drugs through the tar-
geted inhibition of a rate-limiting step in cholesterol biosyn-
thesis. Both clinical and animal studies, however, indicate
that these drugs have beneficial effects unrelated to their
lipid-lowering properties. A key insight into the potential
mechanism for these additional effects was the realization
that the drugs also inhibited isoprenoid biosynthesis and
prevented the geranylgeranylation of rho and that exposure
of vascular cells to the inhibitors caused cytoskeletal
reorganization reminiscent of rho inhibition.7,8 Subsequent
studies have shown that the inhibitors lead to increased
eNOS expression and activation, as well as reduction in tis-
sue plasminogen activator-1 and preproendothelin expres-
sion, and prevention of the growth factor–induced
downregulation of the cyclin-dependent kinase inhibitor,
p27kip1, in vascular cells.9 In the case of increased eNOS
expression, similar effects were observed when the actin
cytoskeleton was disrupted with cytochalasin. Interestingly,
treatment with the treatment of cells with the microtubule
disrupter, nocodazole, reduced eNOS expression. Since
nocodazole increases actin stress fiber formation, these
results suggest that, at least for eNOS, stress fiber formation
actively suppresses its expression.8
Particularly germane to the effect of MLCK and
ROCK inhibitors on attenuating TNF-induced apoptosis
in ECs is the observation that the “statins” activate the
prosurvival Akt/PKB signaling pathway.10 Among the tar-
gets for phosphorylation by Akt/PKB are eNOS, a poten-
tially antiapoptotic signaling molecule whose activity is
increased by phosphorylation and the Forkhead transcrip-
tion factors (FKHR/AFX) whose proapoptotic effects are
inhibited by phosphorylation. While it remains to be
determined whether activation of these Akt-dependent
pathways are important for the apparent survival promot-
ing effects of MLCK/ROCK inhibition, these results
demonstrate an important role for the cytoskeleton in
modulating cytoplasmic signaling.
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NF-κB: A MEDIATOR OF INFLAMMATORY
RESPONSES
Sankar Ghosh
Yale University School of Medicine
New Haven, Conn
Activation of NF-κB by proinflammatory stimuli leads
to the upregulation of genes involved in mounting an
inflammatory response. Induction of NF-κB requires acti-
vation of an IκB-kinase complex containing two catalytic
subunits (IKKα and IKKβ) and the regulatory/adapter
protein NEMO (also known as IKKγ or IKKAP). The
presence of NEMO in the IKK complex is absolutely crit-
ical for proinflammatory signal-induced NF-κB activation,
and it most likely functions to recruit upstream regulators
of IKK activity. Consistent with this, a mutant cell line
lacking NEMO and cells derived from NEMO-deficient
mouse embryos are unable to respond to a wide variety of
NF-κB–inducing signals even in the presence of both
IKKα and IKKβ. We therefore surmised that prevention of
the NEMO/IKK interaction would inhibit signal-induced
activation of IKK function. To test this hypothesis, we
have identified the NEMO-binding domain of the IKKs
and have used this as a target for disrupting formation 
of the core IKK complex. Deletion of the NBD inhibits
cytokine-induced activation of NF-κB, and specific single
amino-acid substitutions within the NBD prevent inter-
action of the IKKs with NEMO. Furthermore, a cell-
permeable NBD peptide specifically disrupts formation of
the endogenous IKK-complex and inhibits both cytokine-
induced NF-κB activation and NF-κB–dependent gene
expression. In addition, the NBD peptide potently ame-
liorates inflammatory responses observed in mice in a
number of distinct experimental models of acute inflam-
mation. These experiments demonstrate that specific inhi-
bition of only NF-κB is sufficient to efficiently suppress
inflammatory responses. Therefore, the NBD represents a
unique target for the development of drugs that would
block cytokine-induced, proinflammatory activation of
NF-κB.
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relationship between exposure of thrombus to the venous
wall and venous wall remodeling with neointimal and
myocellular proliferation. Our results suggest that the
longer thrombus is exposed to the vein wall, the more vig-
orous and sustained is the vascular remodeling and subse-
quent wall thickening. Although this evidence is indirect,
the differences in venous wall morphology between
chronic outflow obstruction with longer thrombus expo-
sure and temporary outflow obstruction with shorter
thrombus exposure in this model are significant. This dif-
ference is even more interesting because chronic outflow
obstruction induced local neovascular channel formation,
whereas temporary outflow obstruction did not.6
It is apparent that thrombus propagation is common
in acute DVT. In plasma the bulk of thrombin generation
takes place after a thrombus has formed, with thrombin
bound to fibrin and fibrinogen within the developing
thrombus. This fibrin bound thrombin remains biologi-
cally and functionally active, within the clot, and subse-
quently as thrombolysis ensues and plasmin degrades the
thrombus.7,8 This clot bound thrombin is protected from
inhibition by heparin-antithrombin III but is susceptible
to newer antithrombin III independent direct thrombin
inhibitors such as hirudin and hirulogs.9 Our model
showed thrombus extension both visually with the vessel
wall dilating and with the radiolabeled fibrinogen assay
over the first 4 days following the acute thrombosis in the
outflow obstruction group, whereas the temporary out-
flow obstruction group did not show thrombus extension.
The thrombosed femoral vein enlarged initially during
creation of the acute thrombosis in both groups, but the
temporarily obstructed group rapidly resolved their DVT
following relief of outflow obstruction. No increased
radiolabeled fibrinogen was detected in the lungs of either
group, so thrombus resolution was a result of thromboly-
sis and not embolization.6
Thrombin is a multifunctional serine protease.
Previously, the main function of thrombin was thought to
be cleavage of circulating proteins to their bioactive forms,
such as fibrinogen to fibrin and activation of protein C.
More recently, thrombin has been recognized as a pluripo-
tent stimulator of various cells. Thrombin is involved in
the associated inflammatory response of thrombosis.
Thrombin is the most potent activator of platelets, it stim-
ulates endothelial cells to express cellular adhesion mole-
cules, to secrete von Willebrand factor, and to elaborate
growth factors and inflammatory cytokines such as TNFα,
macrophage inflammatory proteins (MIP1α and MIP-2),
and monocyte chemotactic protein 1. Inflammation also
stimulates tissue factor expression, which will increase
thrombin generation.
Thrombin is a potent mitogen for fibroblasts and
smooth muscle cells. In organ bath chambers, thrombin is
a potent constrictor of vascular rings denuded of endothe-
lium, yet a potent vasodilator of vascular rings with intact
endothelium. Thrombin has been identified as a promoter
of angiogenesis. Most if not all of these functions have
recently been linked to thrombin stimulation of a mem-
A BIOREGULATORY ROLE FOR THROMBIN
IN VENOUS THROMBOSIS AND
INFLAMMATION
E. John Harris, Jr, MD
Venous thrombosis is far more frequent than arterial
thrombosis, and venous thrombosis is more frequently
clinically occult. Yet the natural history of venous throm-
bosis remains incompletely defined. True natural history
data on the formation and resolution of venous thrombo-
sis and the effects of thrombus on the venous wall are lack-
ing. Venous duplex studies prospectively assessing the
evolution of deep vein thrombosis (DVT) have shown
50% to 70% of limbs with venous thrombosis develop
valvular incompetence 6 to 9 months following the acute
DVT, with thickening of the previously thrombosed but
subsequently recanalized venous wall. Others have identi-
fied duplex findings following recanalization of DVT that
suggest future development of post-thrombotic venous
insufficiency.1 The changes suggestive of chronic damage
included thickening of the vein wall, reflux, and abnormal
valves. A vein wall was considered thickened when it was
twice the thickness of a normal venous segment, with
increased echogenicity of the damaged venous wall
brighter than the normal vessel wall. Recanalized seg-
ments of deep veins show thickened walls in addition to
areas of residual fibrinous thrombus. Loss of normal
venous wall compliance due to this thickening may cause
venous valvular insufficiency, even without damage to the
valve leaflets themselves. Loss of venous wall compliance
may preclude valve leaflet coaptation leading to venous
reflux. Others have shown totally occluded veins more
commonly develop reflux than do veins with only partial
obstruction.2
Pathologic examination of post-thrombotic venous
segments has shown thrombus organization, which
appears to be acutely initiated by inflammatory cell infil-
tration but chronically appears to consist of smooth mus-
cle type fibrocellular proliferation. Historical evaluation of
pathologic specimens from patients suffering from post-
thrombotic venous insufficiency identified a fibrotic thick-
ening of the involved venous segments. Fibrous intimal
thickening was commonly found in the deep veins of the
thighs of the mostly elderly patients studied in this autopsy
series. The time course between acute DVT and the
pathologic examination was not accurately recorded.
Small fibrous strings, ridges and thickenings of the intima,
visible to the naked eye, were found in most patients,
whereas extensive, coarse trabeculated intimal thickenings
and sclerosed lumen-less veins were less frequently
encountered.3,4 In experimental thrombosis models using
pig jugular vein, this thrombus organization appears quite
similar morphologically to neointimal hyperplasia.5
We have developed a model of in vivo deep venous
thrombosis in the rat to assess the role of venous throm-
bosis and outflow obstruction in recanalization and in the
development of secondary venous wall morphologic
changes. This work demonstrates an important temporal
brane bound receptor, which is activated in a novel man-
ner. Most recently, a class of these protease-activated
receptors, or PARs, has been identified.10,11
Protease-activated receptors are members of the seven
transmembrane domain G protein-coupled receptor fam-
ily. The amino terminal of these receptors contains a cleav-
age site that mimics the protease cleavage site. To date
three PARs have been identified in humans: PAR-1 can be
activated by thrombin and trypsin; PAR-2 is activated by
trypsin and tryptase, but not thrombin; and PAR-3, which
is activated by thrombin alone. Receptor activation occurs
when the protease binds the receptor, proteolysis occurs at
the amino-terminal cleavage site by the protease, the pro-
tease is released, and the remaining tethered ligand under-
goes conformational change stimulating the G-protein
cascade. The receptors can also be stimulated by synthetic
peptide agonists that mimic the 5 or 6 terminal amino
acids exposed by proteolysis at the amino-terminus of the
tethered ligand. These PAR receptors therefore contain
their own agonists, the tethered ligands, which in the
naive receptor state are kept quiet by a superfluous peptide
tail. The protease then cleaves this peptide tail allowing
agonist stimulation by the exposed tethered ligand.10,11
As thrombolysis of a venous thrombus is initiated,
active thrombin is likely released locally the lysed throm-
bus. If the thrombus burden is large or there is coexisting
obstruction, this released thrombin can continue to act
locally, either generating new fibrin and extending the
thrombus or stimulating its unique PAR receptor
expressed in the venous wall and on many of the cells of
the local inflammatory cell infiltrate. In this scenario,
thrombin, via its receptor, would stimulate the myoprolif-
erative response that could lead to chronic venous wall
thickening. Furthermore, one thrombin molecule within
the thrombus, excluded from its inhibitors, would be
capable of activating many PARs. If the thrombus is not
obstructing, the active thrombin released locally would be
progressively cleared with blood flow and inactivated by
circulating inhibitors, with minimal chance for interaction
of the thrombin locally with its receptor in the venous
wall. Thus, a small venous thrombus, or nonobstructing
thrombus, would not be expected to elicit myoprolifera-
tive changes and venous wall thickening. We are currently
looking into the role of thrombin and PARs in our model
of chronic venous thrombosis with outflow obstruction. 
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INTEGRIN SIGNALING IN PLATELETS
Michael Sobel, MD
State University of NY
Syracuse, NY
The platelet integrin IIb 3
Integrins are a family of heterodimeric, transmem-
brane receptor proteins composed of noncovalently asso-
ciated and subunits.1 Integrin receptor functions are
governed by subtle changes in the molecular conforma-
tion and intimate association of these subunits. Integrins
serve the functions of cellular anchoring and adhesion to
proteins, generally via the -GRGDS- cell adhesion site of
large molecular weight adhesive proteins like fibronectin,
vitronectin, fibrinogen, and von Willebrand factor.
Beyond adhesive functions, integrins can also transduce
signals back and forth across the membrane, and influence
the flux of calcium and other ions. Considering that cells
as diverse as leukocytes, vascular smooth muscle cells, and
platelets all employ integrins as essential receptors, it is
clear that the integrin family is capable of delivering a wide
repertoire of functions. Through the combination of dif-
ferent and subunits, specific cells express unique integrin
types that have their own favored ligands and preferred
signaling pathways.
The anucleate platelet offers an elegant, simple model
to study the early events associated with integrin engage-
ment of ligand and signal transduction. Large quantities of
these human cells are easily obtained, and can be studied
in nearly natural conditions. There is an established core of
basic information and techniques concerning platelet inte-
grins and their signal transduction mechanisms. The dom-
inant platelet integrin is IIb 3 (glycoprotein IIb/IIIa, or
CD41/CD61), and is unique to platelets. Its favored li-
gand is fibrinogen, but in the absence of fibrinogen, von
Willebrand factor can support platelet aggregation and
hemostasis. The IIb 3 receptor is normally in a low affinity,
unactivated state in resting platelets. By mechanisms still
not fully understood, internal cellular activation converts
this integrin to a high affinity or “activated” form that
binds fibrinogen. The ensuing hemostatic responses—
platelet aggregation, spreading, and clot retraction—are
all dependent on this high affinity, or “activated” state of
the integrin.
Inside-out signaling
First and foremost the platelet is a hemostatic cell with
rapid responses: when exposed to extracellular activators
like thrombin or ADP, platelet aggregation and adhesion
ensue. During cellular activation by these agonists, the
platelet integrin IIb 3 undergoes conformational changes
driven by intracellular activation events. From the integrin’s
point of view, this cellular activation is called “Inside-Out”
signaling, because the internal activation of the platelet
alters the conformation and function of the extracellular
domains of the integrin.2 After “activation” of the integrin,
fibrinogen is bound, receptor oligomerization or clustering
occurs, and there is platelet-platelet clumping and accumu-
lation of platelet thrombus if conditions permit. 
There are two main theories for how this internal cel-
lular activation converts IIb 3 to an active, high-affinity
receptor.3 One pathway clearly involves affinity modula-
tion of the integrin through protein kinase C (PKC).
Thrombin, ADP, and thromboxane A2 all bind to their
own dedicated platelet receptors (7-transmembrane span-
ning receptors), which are linked to heterotrimeric G pro-
teins (most likely Gq) that translate agonist binding into
metabolic cellular activation. This process is quite similar
to the events of muscle contraction, in that it is modulated
by the second messengers cAMP, IP3, and intracellular
Ca2+. PKC (and other protein kinases) are thus activated,
and a number of early phosphorylations of cytoplasmic
proteins ensue. The modulation of the integrin to a high-
affinity state is effected, in part, by the short cytoplasmic
domains of the integrin. Much has been learned about
these cytoplasmic tails through elegant molecular biologic
engineering of integrins with mutated or truncated effec-
tor-tails, as well as peptides that mimic cytoplasmic
domains.4,5 In short, it appears that the final steps in mod-
ulation to high-affinity involve interactions between the
cytoplasmic tails and intracellular regulatory proteins like
3-endonexin, as well as possible transmembrane proteins.
A second, and not mutually exclusive mechanism is
avidity modulation. This theory hypothesizes that a portion
of the integrin receptors are actually restrained from clus-
tering by their attachments to the cytoskeleton in the rest-
ing platelet. Release of these internal cytoskeletal restraints
may enhance integrin avidity through conformational
changes and facilitation of clustering and oligomerization.
This theory is supported by the observations that deletion
of the IIb cytoplasmic domain converts the integrin to a
constitutively activated form, and that uncoupling the inte-
grin from the cytoskeleton increases ligand binding. 
Outside-in signaling
After fibrinogen is bound, receptor oligomerization or
clustering follows. These events lead to “Outside-In” sig-
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naling: the process of letting the inside of the cell know
that adhesive ligands have been seriously engaged. Out-
side-In signaling is manifest in several ways.
LIBS. Ligand-induced binding sites (LIBS) appear
within the extracellular domains of the integrin as a result
of the conformational changes induced by ligand bind-
ing.6 LIBS were serendipitously discovered when it was
noticed that certain monoclonal antibodies only recog-
nized the integrin epitope when ligand was bound to the
integrin. 
Protein translocation. Receptor occupancy and clus-
tering recruits and translocates regulatory proteins to 
the activation-dependent cytoskeleton.7 For example, the
normally soluble Rap proteins (members of the Ras super-
family) are known to rapidly associate with the detergent-
insoluble cytoskeletal fraction during platelet activation
and aggregation.8
Protein phosphorylations. Ligand engagement and
clustering causes tyrosine phosphorylation of the 3 cyto-
plasmic domain.9,10 3-phosphorylation appears to be one
of the earliest markers of Outside-In signaling. The phos-
phorylations of Syk and pp125FAK (FAK) also stem from
signals generated by IIb 3. Integrin clustering alone will
activate the Syk pathway, while FAK requires both cluster-
ing and ligand engagement.
Heparin effects on integrin-mediated signaling
While it has long been recognized that heparin binds
to human platelets, and can cause activation and aggrega-
tion, the precise mechanisms have not been clearly known.
In our focus on heparin-platelet interactions, we recently
identified IIb 3 as a heparin-binding site.11 Because physi-
ologic studies suggested that heparin may modulate this
integrin’s function, we studied the low molecular mass
GTP-binding protein, Rap2B, which is known to become
incorporated into the activation-dependent cytoskeleton
as a result of integrin-mediated signaling. 
Rap2B is normally abundant in the cytosolic fraction
of resting platelets, but translocates to the detergent-insol-
uble cytoskeletal fraction during platelet aggregation and
integrin ligation. These two fractions are easily separated
by centrifugation, and visualized by electrophoresis and
immunostaining of Western blots. 
Thus, in this present investigation of heparin-medi-
ated platelet aggregation, Rap2B translocation served as a
useful marker for the early signaling events mediated by
the integrin IIb 3 and the effects of heparin. 
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Our laboratory has utilized the Lewis rat epigastric
vein to femoral artery interposition graft model of intimal
hyperplasia to investigate the role of inflammatory cells
and their cytokine products during vein graft healing.2,9-11
The crucial advantage of this model over other animal
models of intimal hyperplasia is the easy availability of rat-
specific antibodies for immunohistochemical identification
of cell types and proteins, and of genetic sequences for rat
cytokines, collagens, and other proteins. This has allowed
us to analyze cytokine gene expression in healing vein
grafts both at the level of mRNA and protein.
Disadvantages of this model include the necessity of using
an operating microscope and the thin nature of the rat epi-
gastric vein, which has only one to three smooth muscle
cell layers in the media. We have extensively characterized
this model by light microscopy, immunohistochemistry,
and transmission electron microscopy.2,9-11 The histo-
pathology of the neointima and the vein wall closely mim-
ics that seen in explanted human vein grafts. Between 1
and 4 hours after grafting, the endothelial monolayer
appears attenuated with occasional cell loss. Polymorpho-
nuclear leukocytes are detected at the luminal surface and
beneath the endothelium. By 1 day there is endothelial cell
loss, extensive smooth muscle cell degeneration, and
transmural inflammatory infiltrates consisting primarily of
monocytes/macrophages. Monocytes/macrophages are
not present in the ungrafted epigastric vein. After 1 week
the endothelial monolayer is largely restored with acti-
vated-appearing endothelial cells now covering collections
of mononuclear cells within a fibrin matrix sitting above
the internal elastic lamina. In the adventitia, numerous
proliferating fibroblasts and now myofibroblasts are iden-
tified in association with mononuclear leukocytes. Two-
week vein grafts exhibit a quantifiable eccentric neointima
that contains primarily mononuclear leukocytes in associa-
tion with fibrin and extracellular matrix. The density of
myofibroblasts has increased dramatically in the media and
adventitia, with some early penetration of myofibroblasts
into the neointima. Neointimal cells numbers peak at 4
weeks after grafting, then remain constant. From 4 to 12
weeks the neointima becomes more concentric and thick-
ens secondary to progressive extracellular matrix produc-
tion. The predominate neointimal cell type is the
myofibroblast. The features of late extracellular matrix
synthesis in association with myofibroblasts and low cell
proliferation rates correlates with recent observations in
human vein grafts.12,13 Macrophages persist in the rat vein
wall at late time points aligning along the neointima and
media/adventitial interface. Macrophages have been
observed straddling the internal elastic lamina in human
vein graft explants that are 5 to 6 months’ old.7
The factors and mechanisms that recruit monocytes
and macrophages to vein grafts are currently being inves-
tigated. One likely candidate is monocyte chemoattractant
protein-1,2 a potent monocyte chemotactic and activating
factor that is synthesized by endothelial cells, fibroblasts,
smooth muscle cells, and macrophages.2,14 MCP-1 is con-
stitutively expressed in vascular tissues and we have
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VEIN GRAFT INTIMAL HYPERPLASIA: THE
ROLE OF MACROPHAGES AND THEIR
CYTOKINES 
John R. Hoch, MD
Autologous vein grafts remain the preferred conduit
for many arterial reconstruction procedures. Unfortun-
ately, the process of intimal hyperplasia (IH) compromises
the long-term success of vein grafts. Intimal hyperplasia is
characterized by a thickened neointima composed of mes-
enchymal cells (smooth muscle cells and an extracellular
matrix). It has been proposed that vein graft intimal
hyperplasia begins as a universal wound healing response
to vascular injury that evolves, in some patients, into a
chronic condition of unchecked cellular proliferation and
extracellular matrix deposition.1,2 Central to wound heal-
ing are the recruitment of activated monocytes and
macrophages and the expression of cytokines that influ-
ence cell proliferation and differentiation. Investigators
have long postulated that the development of intimal
hyperplasia involved the upregulation of vascular endothe-
lial and smooth muscle cell–associated cytokines and
growth factors, which could act as paracrine or autocrine
mediators of cell behavior. Graft-infiltrating monocytes
and macrophages are an additional source of cytokines and
growth factors in the vein wall. Experiments have shown
that activated macrophages and their cytokine products
can influence monocyte chemotaxis, induction of smooth
muscle cell (SMC) proliferation and migration, extracellu-
lar matrix production, and fibroblast differentiation.3-6
Multiple investigators have demonstrated mononuclear cell
infiltrates in explanted human vein grafts.7,8 Westerband et
al reported “striking numbers of macrophages and mono-
cytes” in explanted stenotic human vein graft specimens
examined by immunohistochemical techniques.8 These
observations led us to hypothesize that mononuclear
leukocytes play a central role in the healing of vein grafts
and the development of intimal hyperplasia.
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detected weakly detectable MCP-1 mRNA expression in
nongrafted epigastric veins by semiquantitative polymerase
chain reaction (PCR).2,15 After grafting, MCP-1 mRNA
fluctuates in a biphasic manner, with peaks at 4 hours and
1 week. These peaks are followed by detectable MCP-1
immunoreactivity and immediately precede maximal
monocyte/macrophage infiltration peaks at 1 day and 2
weeks.2 It is notable that MCP-1 transcript levels do not
return to baseline at late time points but remain sevenfold
above controls at 8 weeks, coincident with persistent
macrophage infiltration. MCP-1 protein is detected earli-
est (1-4 hours) in the endothelium and in the adventitia
around fibroblasts in the extracellular matrix. By 1 to 4
days patchy luminal staining is seen in endothelial cells and
infiltrating monocytes/macrophages, as well as in the
adventitia. Immunoreactive MCP-1 is seen within the
developing neointima at 1 and 2 weeks surrounding infil-
trating macrophages. After 4 weeks MCP-1 staining is con-
fined largely to the area straddling the internal elastic
lamina, colocalizing with ED1+ macrophages. The persis-
tence of MCP-1 mRNA and protein expression in rat vein
grafts at late time points supports the premise that intimal
hyperplasia is an aberrant wound healing response and that
macrophages play a role in its modulation. Importantly,
antibodies against MCP-1 have been shown to decrease
intimal hyperplasia in a rabbit arterial injury model.6
To test the hypothesis that monocytes/macrophages
play a central role in the development of intimal hyperplasia,
we selectively depleted macrophages with liposome-
encapsulated dichloromethylene bisphosphonate (L-
Cl2MBP) and observed the effects on rat vein grafts.17
Cl2MBP is used clinically as a treatment for tumor-induced
hypercalcemia, inhibiting bone resorption by impairing
osteoclast activity. Encapsulation into small multilamellar
liposomes allows specific targeting of the drug to cells of the
mononuclear phagocyte lineage. Cl2MBP is metabolized to
a toxic ATP analog, which interferes with normal metabolic
activity and can lead to macrophage apoptosis.18 Near com-
plete depletion of splenic and hepatic macrophages, as well
as circulating monocytes, occurs 24 to 48 hours after a sin-
gle intravenous injection.19 Rats were injected with L-
Cl2MBP 2 days before placing epigastric vein to femoral
artery interposition grafts. At 1 and 2 weeks there was a sig-
nificant reduction in graft-infiltrating monocytes/
macrophages in L-Cl2MBP treated animals compared to
controls.17 Neointimal area was also reduced at 1 and 2
weeks. At 4 weeks, as levels of circulating monocytes are
restored, macrophage numbers and neointimal areas in L-
Cl2MBP treated grafts were similar to controls. A second
group of rats received an additional dose of L-Cl2MBP at 2
weeks postgrafting. With a second dose of L-Cl2MBP, both
macrophage numbers and neointimal areas were significantly
reduced at the 4 week time point compared to both controls
and the single L-Cl2MBP dose treated group. Although we
cannot rule out a direct effect of L-Cl2MBP upon the vein
wall, the results indicate that intimal hyperplasia is sup-
pressed as macrophages are depleted, with a resumption of
IH as monocytes/macrophages repopulate the vein graft.
The mechanism by which macrophages modulate
intimal hyperplasia remains to be defined. In our early
experiments with this model, we utilized qualitative PCR
to screen for macrophage-associated cytokines that might
influence intimal hyperplasia.9,10 We postulated that an
understanding of the in vivo cytokine transcriptional
events occurring during different stages of intimal hyper-
plasia might allow targeting of specific genes or cell types
for the development of new therapeutic strategies.
Interleukin-1α (IL-1α) mRNA is upregulated from 4
days to 4 weeks in rat vein grafts.9 Platelet-derived
growth factor–A (PDGF-A) mRNA is expressed in
ungrafted control veins but its expression is downregu-
lated at 1 and 4 hours, coincident with endothelial cell
loss. By 4 days PDGF-A mRNA is detectable with con-
tinued expression out to 2 weeks when quantifiable inti-
mal hyperplasia is present. Transforming growth factor
beta (TGF-β1) mRNA was weakly detected in ungrafted
epigastric veins.9,10 Variable induction of TGF-β1 gene
transcription was evident at 1 and 4 hours, with promi-
nent mRNA expression from 1 day to 2 weeks.10 Recent
semiquantitative PCR analysis indicates peak TGF-β1
mRNA expression at 4 days (unpublished). Bioactive
TGF-β1 protein expression, assessed by immunostaining,
peaks at 4 weeks, with greater than 70% of vein wall cells
staining for TGF-β1 at 12 weeks. TGF-β is a pleiotropic
cytokine that may modulate intimal hyperplasia through
its powerful effects on inflammatory cell chemotaxis,
SMC, EC, and fibroblast proliferation, extracellular
matrix synthesis, and fibroblast differentiation into myofi-
broblasts. Current investigations are focused on manipu-
lating TGF-β1 gene expression within healing rat vein
grafts to determine whether TGF-β1 is integral to the
development of intimal hyperplasia.
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PDGF.6-8 ERK (extracellular signal-regulated kinases) are
signaling molecules activated by phosphorylation sec-
ondary to growth factor binding.9,10 The purpose of this
study was to evaluate the amount of intimal hyperplasia,
the presence of macrophages, and the role of Egr-1 and
ERK-2 in this rat aortic interposition vein graft model.
METHODS
We have developed a model of intimal hyperplasia that
occurs in a rat model that is reproducible, quantifiable, and
clinically relevant. In this model, the right external jugular
vein is harvested using minimal periadventitial dissection.
The abdominal aorta was dissected and divided, and the
jugular vein was anastomosed in an end-to-end fashion.
The rat vein grafts were then excised after periods of 24
hours, 4 weeks, 8 weeks, and 12 weeks after implantation.
Some of the grafts were explanted after being perfu-
sion-fixed in situ with 4% paraformaldehyde and stored in
formaldehyde for histologic analysis. The formalin-fixed
tissues were serially cut from proximal to distal anastomo-
sis into transverse sections. Sections were processed rou-
tinely through graded alcohols and xylene and embedded
in paraffin. Five-micron thick sections were cut and
mounted on glass slides. For routine microscopy, serial sec-
tions were stained with hematoxylin and eosin (H & E)
and a combined trichome/elastin stain. The H & E stained
delineated the cellular components of the tissue while the
trichome/EVG delineated the connective tissues, namely
elastic fibers, collagen, and smooth muscle cells.
For immunohistochemical staining, other histologic
sections were deparaffinized and rehydrated in graded
alcohols. Endogenous peroxidase activity was blocked
with 3% hydrogen peroxide for 10 minutes. Sections were
washed in PBS and a commercial blocking agent was
applied. Primary monoclonal antibodies used were mouse
anti-rat actin (1:400) and ED2 for macrophages (1:400).
The remainder of the procedure consisted of an avidin-
biotin-peroxidase technique with diaminobenzidine as the
chromagen. Slides were then counterstained in weak
hematoxylin for 1 minute, washed, and dehydrated, and a
coverslip was placed over the specimen.
Western blot analysis was performed on lysates of the
rat vein graft tissues that had been minced and
homogenated after being flashed frozen. Additionally, the
tissue samples were sonicated and the soluble fraction was
isolated. Proteins were fractionated on 10% acrylamide
gels, and 30 g of protein were loaded at each time point.
Western blots were probed with anti–Egr-1 polyclonal
antibody and mouse anti–ERK-2 monoclonal antibody.
RESULTS
The normal jugular vein is composed of an endothelial
cell monolayer resting on a very thin medial smooth mus-
cle cell layer composed of only a few layers of smooth mus-
cle with surrounding containing collagen fibers.
At 24 hours, no evidence of intimal hyperplasia was
seen. Egr-1 was not present at 24 hours nor was ERK-2.
At 72 hours, the endothelial cell layer is denuded and the
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INTRODUCTION
The present day understanding of neointimal hyper-
plasia and its underlying mechanisms are based largely on
arterial injury models.1 Extrapolation of these data to
neointimal hyperplasia in the vein graft may be inappro-
priate as the structure of the vein and its response to injury
may be materially different from an artery. The vein is
structurally and functionally distinct from the artery and as
such the response of the vein to injury may be very differ-
ent from the artery. The presence of macrophages have
been noted by some to be present during this process of
neointimal hyperplasia.2,3 The vein that has been placed
into the arterial circulation becomes thickened, a process
called by some “arterialization” and this occurs particu-
larly at the anastomosis.4,5 This can lead to early graft fail-
ure requiring intervention.
In several arterial injury models, Egr-1 has been
shown to be involved in neointimal development. Egr-1
has been shown to induce transcription of TGF-alpha and
medial layer appears disrupted. There was no fibrin and
platelet deposition on the vein luminal surface. There was
very little discernible infiltration of the vein wall by any
other cell types.
By 2 weeks, there was a discernible neointima/medial
layer that was composed of cellular elements and matrix
that stained positive for collagen (trichome stain). There
were only a few inflammatory cells present with occasional
macrophages seen. The macrophages were identified by
being ED2 positive. The majority of the cells at this time
point did not stain positive for ED2.
At 4 weeks, there was prominent neointimal thickening
with significant matrix deposition. The neointima stained
strongly positive for collagen. At this time point, the pre-
dominant cell type was alpha-actin positive, which implied
that the cells may be derived from smooth muscle cells or
myofibroblasts. Again, very few macrophages were seen in
the neointima or in the vein wall itself, comprising less than
10% of the cells. Additionally, Egr-1 was present at its peak
at 4 weeks but not ERK-2. Egr-1 remained present at 8
weeks as well, and ERK-2 had its peak at 8 weeks.
At 12 weeks, the neointimal thickening persisted and
showed no evidence of progression. The endothelium
appeared to be reconstituted and the cells, and matrix con-
tinued to stain positive for alpha-actin. New focal calcifi-
cations were seen in the vein graft at this time point were
also present. Egr-1 was still present at 12 weeks. ERK-2
was also present. Both Egr-1 and ERK-2 declined by the
12-week period.
DISCUSSION
Stark and colleagues have suggested that an aberrant
healing response is responsible for vein graft neointimal
hyperplasia in their model.4,5 They have shown that early
after the vein is implanted into the arterial circulation, the
smooth muscle cell layer in the vein graft is destroyed.
The repopulation of the intima may be adventitial fibro-
blasts or myofibroblasts rather than medial smooth mus-
cle cells. This repopulation of cells is really a composite
neointima that is delineated only by an external elastic
lamina without an apparent boundary between an intima
and media—no internal elastic lamina. This is in marked
contrast to the normal vein medial layer, which is at most
a few cell layers thick.
The development of neointimal hyperplasia in our
model is comparable to others that have published in this
area. The early events after vein grafting are denudation of
the endothelial cell layer and destruction of the smooth
muscle cells in the media. There appears to be enhanced
proliferative activity in the adventitia, followed by repopu-
lation of the intimal layer by alpha-actin positive cells.
Macrophage infiltration occurs early in the first 2 weeks
but is not a prominent feature of the lesion after that time
point. ERK-2 and Egr-1 are present in our vein graft
model, and they peak at 8 weeks and 4 weeks, respectively,
and may be involved in the pathways leading to neointimal
hyperplasia in this rat model of vein graft neointimal
hyperplasia.
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The lesions of atherosclerosis localize in distinct sites
within the vasculature, especially affecting the coronary
arteries, the major branches of the aortic arch, and the
abdominal aorta and its visceral and major lower extremity
branches.1 Our laboratory and others have been rigorously
studying the influence of hemodynamic forces on vascular
cell biology and its impact on atherogenesis. The endothe-
lium is not merely a vessel lining: it participates actively in
the interactions between the vessel wall and the dynamic
fluid environment of blood.2 It has been our hypothesis
that static conditions commonly utilized to study vascular
cells in culture may not reflect their in vivo milieu.
In our laboratory, we expose vascular endothelial cells
(ECs) to cyclic strain using flexible-bottom culture plates
and subjecting them to vacuum deformation at repeating
cycles of elongation and relaxation. Cyclic strain causes
certain functional and structural responses when applied
to EC. EC responses to cyclic strain include morphologic
changes,3 proliferation,4 and migration.3 Cyclic strain also
induces the synthesis of many macromolecules, including
tissue plasminogen activator,5 nitric oxide synthase,6
endothelin,7 and prostacyclin.8
The impetus in the field has shifted from a description
of phenotypic modifications of ECs exposed to external
forces to a more mechanistic investigation of the bio-
chemical pathways which link cell surface events to nuclear
responses.9 This talk will summarize current research,
which has aimed to elicit the signal transduction pathways
by which cyclic strain elicits functional and structural
responses in ECs; specifically, we will review the transduc-
tion pathway that begins with the reorganization of inte-
grins and proceeds to the phosphorylation of cytoplasmic
protein tyrosine kinases (PTKs), the involvement of
nuclear transcription factors, and ultimately the regulation
of gene expression.
Integrins are extracellular matrix (ECM) receptors,
which are concentrated in focal adhesions (also known as
adhesion plaques or focal contacts) and bind to certain
cytoskeletal proteins. They appear to function as mechano-
transducers, capable of coupling outside forces to bio-
chemical signals.
Cyclic strain has been found to induce the reorganiza-
tion of vascular EC integrins, specifically α5β1 [a
fibronectin receptor] and α2β1 [a collagen-I receptor].
Yano et al10 showed that β1 integrin reorganized in a 
linear pattern with the long axis of the elongated cells, 
creating a fusion of focal adhesions in collagen- or
fibronectin-plated ECs after 4-hour strain exposure. Cyclic
strain also led to the reorganization of α5 and α2 integrins
in a linear pattern in ECs seeded on fibronectin or colla-
gen, respectively; once again, integrins were more concen-
trated and aligned along the long axis of ECs creating a
large fusion of focal adhesions. The expression of integrins
α5, α2, and β1, however, did not change even after 24-
hour exposure to strain. This was the first report that
strain reorganizes and fuses integrins in ECs without
affecting their levels of surface expression.10
The tyrosine phosphorylation of cytoplasmic PTKs
serves as a method for signal transmission into the cell.
Integrins play an important role in transducing cyclic
strain stimulation into intracellular signals; one potential
mechanism, by which integrins affect signal transduction,
is through their ability to initiate the process of phosphor-
ylation on tyrosine residues of cytoplasmic kinases. A
major substrate for integrin-induced tyrosine phosphory-
lation is the PTK focal adhesion kinase (FAK or
pp125FAK), whose autophosphorylation leads to the acti-
vation of other PTKs.11 The clustering of β1 integrin is
known to induce FAK phosphorylation,12,13 via an unde-
fined mechanism. Yano et al10 speculate that the integrin
α subunit acts as a mechanotransducer by sensing and
responding to strain, while the β1 integrin cytoplasmic
domain relays the signal into the cell. 
Focal adhesions are discrete regions of the plasma mem-
brane that allow many cells, including EC, to adhere tightly
to the underlying substrate.14 In these regions, the plasma
membrane is specialized at its cytoplasmic face for anchor-
ing stress fibers and so provides a link between the ECM
and the cytoskeleton.14 Furthermore, since regulatory pro-
teins have been identified in focal adhesions, it appears that
these regions are involved in transmembrane signaling
between the extracellular environment and the cytoplasm.14
pp125FAK is a cytoplasmic PTK, which localizes to
sites of cellular focal adhesions, hence the designation—
focal adhesion kinase.15 Characterization of this protein
was derived from experiments using Rous sarcoma virus
(RSV)–transformed cells (which express the virus-encoded
oncoprotein pp60v-src-a PTK, and have elevated levels of
pp60v-src at focal adhesions), since the level of tyrosine
kinases in nontransformed cells is too low to detect by
immunofluorescence microscopy.15
Yano et al3 showed a significant increase in tyrosine
phosphorylation of pp125FAK in EC by 30 minutes (3.4-
fold) and 4 hours (5.9-fold) of exposure to cyclic strain.
This was the first report of induction of pp125FAK by a
mechanical force. They showed that high strain induced a
redistribution and reorganization of pp125FAK, as well as
F-actin and paxillin; the protein aligned with the long axes
of ECs, which began to elongate after 4 hours’ exposure
to strain. The data suggested that tyrosine phosphoryla-
tion of FAK (and paxillin) may regulate the reorganization
of F-actin and the morphological changes induced by
strain. Furthermore, their data demonstrated that FAK
may have a role in strain-enhanced EC migration.
Extracellular signal-related kinases (ERK) 1 and 2,
members of the mitogen-activated protein (MAP) kinase
family, are ubiquitous components of signal transduction
pathways.16 They are activated by diverse extracellular
stimuli,16 and have been shown to mediate cell responses
to physical forces.17 Tseng et al19 reported activation of
ERK 1 and 2 by physiological levels of shear stress in a
time- and force-dependent manner. It was the first study
to document that a Ca2+-independent signal transduction
pathway was stimulated by flow in EC.18
Ikeda et al19 demonstrated that cyclic strain stimulates
ERK 1 and 2 phosphorylation and activation in a time-
and strain-dependent manner. Phosphorylation was signif-
icantly increased as early as 5 minutes; activation was
shown to peak at 10 minutes—the same time as shear
stress-induced EC activation.18 This activation was inde-
pendent of Ca2+ flux and completely regulated by tyrosine
kinases. ERK 1 and 2 activation was required for basal pro-
liferation of ECs, but did not appear to be involved in
strain-induced increases in proliferation or in changes in
cell orientation.19
P21-ras (ras), a small guanosine triphosphate (GTP)–
binding protein, has been shown to play an important
role in the signal transduction pathways to extracellular
mitogenic stimulation.20 It is a protein that is active in
the GTP-bound state and inactive in the guanosine
diphosphate (GDP)–bound state. Li et al21 reported that
ras is activated by shear stress in ECs maximally at 
1 minute.
Cyclic strain also induced a transient activation of ras
in a time-dependent manner (peak at 1 minute) in vascu-
lar endothelial cells.20 This study demonstrated for the
first time that strain stimulates the conversion ratio to
GTP-bound ras (from GDP-bound ras) and suggested the
involvement of ras in the signal transduction pathway lead-
ing to strain-induced ERK 1 and 2 activation.20
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pp60-src (src) is the best characterized protein tyro-
sine kinase and the prototype PTK of the cytosolic nonre-
ceptor family.22 It colocalizes with integrins within focal
adhesions, supporting the assumption that mechanical sig-
nals are transduced into biochemical information via
chemical signaling molecules.23
Schaller et al15 showed an elevation in the phosphoty-
rosine content of FAK in pp60v-src –transformed chicken
embryo (CE) cells. They attributed this observation to
certain possible scenario.15 First, it was possible that there
was increased autophosphorylation due to FAK’s activa-
tion by an as yet undefined mechanism. Second, pp60v-src
may have activated an endogenous PTK, which subse-
quently phosphorylated FAK. Or third, it was possible
that pp60v-src itself directly phosphorylated pp125FAK.
Nevertheless, the fact that the autophosphorylation
mutant FAK397 [phenylalanine substituted at tyrosine
residue 397 (Tyr-397) of FAK] fails to form a complex
with pp60src in src-transformed CE cells demonstrates that
autophosphorylation at Tyr-397 is necessary to create the
binding site for pp60src.11
Jalali et al24 showed that src plays a critical role in the
shear stress activation of MAP kinase pathways and induc-
tion of EC transcription factors. Furthermore, the FAK-
mediated association and activation of src was shown to
be essential for maximal signaling to ERK 2.25 The ques-
tion of a role for src in cyclic strain-induced signal trans-
duction arose.
Our data indicate that src is phosphorylated and acti-
vated with the application of stretch in EC in a time-
dependent fashion. Peak phosphorylation of src occurs at
5 minutes, and peak activation occurs at 5 to 10 minutes.
Further, our studies show that src is coimmunoprecipi-
tated with FAK, implying that the two kinases interact
directly.
CONCLUSION
Downstream of the aforementioned events, MAP
kinase family enzymes are known to translocate into the
nucleus26 and phosphorylate transcription factors.27 It is
the regulation of gene expression through the modula-
tion of transcription factors that allows ECs to respond
to changes in local hemodynamics.28 Future treatments
for atherosclerosis may focus on targeting short amino
acid sequences on PTKs and inhibiting atherosclerosis-
implicated gene expression in predisposed sites within
the vasculature.
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FLUID FLOW REGULATES TRANSLATION IN
ENDOTHELIAL CELLS
Larry W. Kraiss
Andrew S. Weyrich
Thomas M. McIntyre
Guy A. Zimmerman
University of Utah
Salt Lake City, Utah
Similar mechanisms regulate transcription and 
translation
A cell’s phenotype becomes apparent when informa-
tion stored in its genes is converted into functional pro-
teins through the processes of transcription and
translation. It has long been recognized that transcrip-
tional events are tightly controlled with numerous signal-
ing pathways and regulatory systems having been
characterized. The cell also separately controls translation
of mRNA into protein by mechanisms that resemble those
that regulate transcription.1 Phosphorylation cascades
transmit extracellular signals to the translational apparatus
similar to the way signals are communicated to the
nucleus. In other instances, trans-acting proteins either
promote or inhibit translation through sequence-specific
interactions with regulatory regions in the mRNA mole-
cule—similar to the way transcription factors control DNA
transcription. Further, both transcription and translation
require the formation of preinitiation complexes that are
strikingly similar in structure.
Fluid flow is a well-described regulator of transcrip-
tional signaling in endothelial cells.2 Our laboratory is
studying how fluid flow can similarly regulate translational
signaling events in endothelial cells.
The mTOR translational control pathway
The mammalian target of rapamycin (mTOR) is a
central kinase in a well-characterized signaling pathway
that controls translation.3 The mTOR pathway regulates
cell growth and derives its name from rapamycin, an
immunosuppressant drug that inhibits activation of this
pathway. Upstream signaling to mTOR is largely medi-
ated by phosphatidylinositol 3-kinase (PI3K). mTOR
then signals to at least two different downstream tar-
gets—the P70/P85 S6 kinase (pp70S6k) and the eukary-
otic initiation factor 4E (eIF4E)-binding proteins
(4E-BPs)—to activate translation. When phosphorylated,
pp70S6k facilitates translation of mRNA transcripts with
5´ oligopyrimidine tracts (transcripts for many ribosomal
proteins). The 4E-BPs regulate the activity of eIF4E, an
essential component of translation initiation complexes
that process mRNA molecules with long, complex 5´-
untranslated regions. The mTOR pathway was originally
characterized in lymphocytes and fibroblasts. Our labora-
tory has demonstrated that mTOR is present in endothe-
lial cells (HUVEC) and can be strongly activated by
histamine and oncostatin M. Other agonists such as LPS,
TNF-α, IL-1, and phorbol esters induce moderate levels
of activation. 
Fluid flow activates pp70S6k and translation of Bcl-3
in endothelial cells
Using activation of pp70S6k as a readout, we studied
the ability of fluid flow to activate the mTOR pathway.4
Peak shear stresses of > 4 dyn/cm2 were required to pro-
duce a phosphorylation-dependent mobility shift of
pp70S6k on Western blots and to visualize activated
pp70S6k isoforms using phospho-specific antibodies.
Activation occurred within 5 minutes after onset of flow
and returned to baseline by 60 minutes. A survey of vari-
ous cell types revealed that only endothelial cells and aor-
tic SMC transduced the shear signal to pp70S6k.
Rapamycin and wortmannin (a PI3K inhibitor) blocked
activation of pp70S6k by flow. 
The mRNA transcript for Bcl-3 has certain properties
that suggest its translation is regulated by the mTOR
pathway: a 5´-untranslated region with a high degree of
secondary structure along with the presence of multiple
polypyrimidine tracts.3,5 Translation of Bcl-3 in
platelets—cells that are incapable of transcription––is
dependent upon activation of the mTOR pathway.5 Based
on this information, we predicted that endothelial trans-
lation of Bcl-3 would be upregulated by flow. We found
that Bcl-3 synthesis was induced by flow with kinetics that
resembled pp70S6k activation, occurred even when tran-
scription was blocked by actinomycin D, but was blocked
by rapamycin. These data indicate that activation of the
mTOR pathway by fluid flow can specifically affect how
certain transcripts are handled by the endothelial transla-
tional apparatus.
The mTOR pathway mediates fluid flow-induced
DNA synthesis in endothelial cells
The major biological function of the mTOR path-
way is to regulate cell growth.6 We therefore asked
whether activation of mTOR by fluid flow would
result in endothelial cell proliferation. We also com-
pared the relative contributions to cell growth of 
a flow-activated transcriptional signaling cascade
(ERK1/2) with the mTOR translational control path-
way.7 Application of oscillatory flow to HUVEC
monolayers activated both the ERK1/2 pathway and
pp70S6k. Pharmacological inhibition with PD98059
and rapamycin blocked flow-induced activation of
ERK1/2 and pp70S6k, respectively. Oscillatory flow
also induced HUVEC cultures to take up [3H]thymi-
dine and upregulate cyclin-dependent kinase 1 expres-
sion, consistent with a growth response. While
rapamycin completely abolished flow-dependent DNA
synthesis, PD98059 did not. Rapamycin also inhibits
injury-induced intimal hyperplasia.8,9 Taken together,
these results indicate the potential importance of this
translational control pathway in determining the ulti-
mate phenotype of the blood vessel.
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Why separately regulate translation?
The separate control of translation (apart from tran-
scription) is advantageous for several reasons. First, trans-
lation is one of the most energetically expensive tasks a cell
performs, consuming four high-energy phosphates to add
one residue to a growing polypeptide. If insufficient
resources (energy or amino acids) were available to com-
plete translation of an mRNA transcript, failure to prevent
initiation of translation even in the presence of available
mRNA, would be wasteful of the cell’s already limited
resources.
Second, many proteins such as oncogenes, growth fac-
tors or intermediates in mitogenic signaling pathways are
potentially dangerous and merit redundant regulation by
the cell. mRNA transcripts for these kinds of proteins
often contain long 5´-leader sequences with extensive sec-
ondary structure that require unwinding or special han-
dling by the translational apparatus before translation
initiation occurs.10
Third, regulating translation allows the cell to respond
to external stimuli more quickly by producing protein
from existing pools of mRNA than if new transcription
were required. The rapid production of Bcl-3 in response
to flow is an example of this feature.
Vascular biologists have largely focused on transcrip-
tion and ignored translational control as a means of regu-
lating vascular cell phenotype. Given the diversity of
transcriptional control mechanisms already characterized
and the similar mechanisms used to control translation, it
is likely that numerous additional translational control
pathways will be identified and shown to be active in the
vessel wall. 
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SIGNALING IN EX VIVO PERFUSED
VASCULAR CONDUITS
Satish C. Muluk, MD
University of Pittsburgh School of Medicine
Here in the 21st century, it is widely recognized that
the hemodynamic and biomechanical environment of the
blood vessel has a profound influence on the molecular
expression and physiology of its constituent cells. This
fact, however, has only become clear in the last one or two
decades. The concept that cytoplasmic and nuclear bio-
chemical events can be influenced by deformation of the
cell membrane and the cytoskeleton seems self-evident,
but only in the context of years of investigation into cellu-
lar responses to mechanical forces.
Various approaches to the topic of force-related effects
on vascular tissue are available. Cell culture studies allow
detailed molecular mechanistic studies and precise control
of conditions. However, the clinical significance of
observed effects is often in doubt. Although various
hemodynamic forces can be mimicked with specialized
devices, it remains difficult with cell culture to reproduce
proper organ geometry and in vivo deformations. Also
important is the difficulty of accounting for the roles of,
and interactions between, the various cell types that com-
prise the blood vessel. For example, it is conceivable that
endothelial responses in vivo result from production of
cytokines by smooth muscle cells. 
Animal models provide a more clinically relevant envi-
ronment for study than cell culture studies. However,
experimental parameters such as hemodynamic conditions
and drug administration cannot be precisely controlled.
An animal model also limits the endpoints that can be
examined. Furthermore, an in vivo model virtually elimi-
nates the possibility of studying human tissue.
Ex vivo perfusion of intact vessels serves as a useful
third method to study biomechanical effects. Study of the
whole “organ” (ie, the intact blood vessel) is more clini-
cally relevant than cellular studies, and the ex vivo envi-
ronment allows for precise control of hemodynamic and
treatment parameters. Human tissue can also be studied in
such ex vivo settings, although it should be noted that
such tissue is not easily obtained. Despite the utility of
whole vessel study, detailed molecular mechanisms often
cannot be studied because of lack of adequate cell num-
bers. In addition, ex vivo perfusion apparatuses are rela-
tively expensive to set up and maintain. The conduits are
also difficult to obtain, and it is difficult to perfuse more
than a few vessels at a single setting. Perhaps for these rea-
sons, studies using perfused intact vessels are far fewer
than either animal or cell culture studies.
These various methods of approach are not competi-
tive but complementary. An optimal strategy would use the
different methods in combination in order to fully under-
stand the molecular mechanisms and clinical relevance of
changes caused by biomechanical forces. Numerous bio-
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logic effects have been examined in perfused vascular con-
duits. In many cases, these effects could not have been eas-
ily studied in other models. This review will examine
various themes that run through this body of research.
The review is not intended to be exhaustive, but instead its
purpose is to give the reader an overview of the field as
well as insight into the research advantages of using per-
fused whole vessels.
Theme 1: Complex biomechanical forces
A key limitation of cell culture studies is the difficulty
of studying the complex three-dimensional deformations
that affect real vessels. Recently, various investigators have
designed sophisticated perfusion systems designed to
mimic such complex deformations. This approach is exem-
plified by the work of Vorp and colleagues.1,2 Their appa-
ratus allows for the study of deformations such as cyclic
bending, twisting, and stretching. These forces affect
human vessels crossing joints and those in the heart. In
their analysis of cyclic bending,1 their group found that E-
selectin and matrix metalloproteinase-1 (MMP-1) were
consistently and significantly downregulated in the speci-
mens subjected to 4 hours of cyclic bending.
Theme 2: Thrombogenicity of blood vessels
The intact vessel is much more than a mere conduit
for blood. A key result of vascular research is that endothe-
lial and smooth muscle cells play a crucial role in main-
taining the anti-thrombotic phenotype of the vascular
lumen. These cells can express (or fail to express) genes
that govern the production of molecules and surface
receptors that affect vessel thrombogenicity. It is no sur-
prise that numerous investigators have examined throm-
bogenicity in perfused ex vivo conduits. For example,
Zurbano et al3 found that cocaine administration to pigs
enhances platelet reactivity of damaged coronary arteries.
Platelet reactivity is difficult to measure in vivo, but the
authors were able to measure this endpoint in an ex vivo
perfusion system. They concluded that this effect might
explain myocardial infarctions seen in cocaine users.
Muluk et al2 examined the effect of various biomechanical
forces on expression of tissue factor (TF) by human saphe-
nous vein. Arterial perfusion conditions were found to
enhance TF expression significantly in comparison with
venous conditions. An even greater increase in TF expres-
sion was seen with ex vivo perfusion conditions designed
to simulate the coronary artery (arterial hemodynamics
with twisting and stretching forces characteristic of the
beating heart). The authors concluded that their findings
might explain the early thrombogenicity of arterial bypass
grafts, especially those used for coronary revascularization.
Theme 3: Regulation of vascular tone
The regulation of vascular tone, an issue of great clin-
ical importance, has been traditionally studied with iso-
lated vascular rings or isolated strips of vessel. However, a
more physiologic analysis can be obtained with perfused
intact vessels. In an early example of this type of work,
Ligush et al used canine carotid arteries to study the
effects of nitric oxide.4 The work of Brophy’s group in
Georgia is another good example of this type of study. For
example, her group recently showed that smooth muscle
cell responses in a muscle bath are different from
responses of intact vessels.5 One difference was that whole
vessels were more sensitive to norepinephrine than the
muscle strips. They suggested that intact vessel responses
might more closely approximate in vivo responses. 
Theme 5: Vascular permeability
Vascular permeability, particularly at the microvascular
level, plays a key role in many pathophysiologic states.
One recent study6 examined the role of guanosine 3´,5´-
cyclic monophosphate (cGMP) as a modulator of perme-
ability. cGMP alone was found to transiently increase basal
permeability, and it also potentiated ATP- and bradykinin-
induced increases in vessel permeability. These effects were
found to be independent of endothelial calcium concen-
trations.
Theme 6: Cellular adhesion
Adhesion of cellular elements to the vessel wall is now
known to play a key role in multiple clinical settings,
including atherosclerosis, inflammation, and thrombosis.
In vivo, only indirect inferences can be drawn about cellu-
lar adhesion in most cases. The work of He et al7 exem-
plifies precisely controlled cellular adhesion study in ex
vivo perfused vessels. This group found that leukocyte
adhesion to frog vessels significantly increases vessel per-
meability. Because of the ex vivo setting, the investigators
were able to measure permeability before and after allow-
ing leukocytes to adhere to the vessels. The permeability
increase could be mitigated by antioxidant administration.
Theme 7: Microvascular anastomoses
Animal studies of vascular anastomoses or large and
medium vessels have been very fruitful. However,
microvessel anastomoses cannot be easily studied in vivo.
The work of Dumanian et al8 demonstrates the use of a
placental artery model of a perfused microvascular anasto-
mosis. This study showed the importance of tissue factor
as a thrombogenic element at such anastomoses.
Theme 8: Effects of endovascular devices
The proliferation of new endovascular devices has pro-
vided another role for ex vivo perfusion studies of intact
vessels. In an early example of this type of work,
Bergqvist’s group in Sweden examined the effect of trans-
luminal angioplasty on prostanoid release from the arterial
wall.9 This end point could not have been easily measured
in vivo, but it could be measured in their ex vivo model.
The release of prostacyclin was significantly reduced 
by angioplasty whether or not the medium was supple-
mented with arachidonic acid. The authors concluded that
endothelial denudation was the probable cause of their
observations.
Conclusion
This brief summary of existing studies of perfused vas-
cular conduits should make it clear that this methodology
is uniquely suited to answer important questions in vascu-
lar biology. The challenge to the investigator is to combine
various methods of analysis so that a truly comprehensive
understanding of the above topics can be achieved.
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SIGNALING IN THE VESSEL WALL IN WHOLE
ANIMALS
Scott Berceli
Mark Davies
Richard Kenagy
Alexander Clowes
The local hemodynamic environment, as mediated by
shear stress and mechanical tensile forces, is integral in the
normal function and pathologic dysfunction of the arterial
vasculature. The initial localization and subsequent devel-
opment of atherosclerotic lesions, the adaptation and
remodeling within autogenous vein bypass grafts, and the
disruption of vulnerable atherosclerotic plaques are all
controlled by the pressure and flow patterns within the
vessel lumen. 
Hemodynamic forces are sensed and transduced
within individual cells through deformation of the
cytoskeleton and cell membrane. Local activation of inte-
grins and ion channels within the cell membrane as well as
tensegrity-modulated pertubation of distant cellular func-
tions have been ascribed a role in this transduction
process. Activation of these sensors and receptors initiates
a complex intracellular response occurring at multiple lev-
els, via second messenger pathways, transcriptional activa-
tors and inhibitors, and posttranslational modifiers of
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RNA and protein synthesis. The interplay of these intra-
cellular events leads to alterations in the structure and
function within the affected cell as well as changes in the
local production of mitogenic factors and vasoactive
agents. These changes in the local cellular milieu regulate
the growth, death and migration of cellular elements, the
synthesis and degradation of matrix components, and 
the permeability and adhesion molecule expression of the
endothelium, thus governing the normal biology and
abhorrent pathobiology of the surrounding arterial wall.
Most of the current information on the transduction
of hemodynamic forces and the resulting changes in cell
function has been obtained using cell culture systems.
These systems allow the flexibility to investigate the effect
of a specific hemodynamic stimulus on the immediate and
short-term response of an isolated cell population.
Through these models, multiple genes and autocrine and
paracrine factors, which are regulated by tensile and shear
stress, have been identified. Among the most studied ele-
ments include growth factors and receptors (PDGF, FGF,
EGF, VEGF), vasoactive molecules (NO, prostaglandin),
matrix-associated proteins (collagen, elastin, metallopro-
teinases), cell cycle genes and transcription factors (p38,
p21, p27, c-jun, c-fos, NFκB), and cell adhesion mole-
cules (ICAM, VCAM, cadherin). While each of these fac-
tors has been shown to be modulated by hemodynamics in
isolated culture systems, the key regulators of the process
of intimal hyperplasia or the responders to an altered
hemodynamic environment that are most prominent in
vivo have not been as well defined.
Models
In our laboratory we have continued to employ a pri-
mate/PTFE graft model to understand the effects of flow-
induced intimal hyperplasia. Using a “flow switch”
configuration, bilateral PTFE aorto-iliac bypass grafts are
implanted, with simultaneous placement of bilateral
femoral arterio-venous fistulae.1 Following an 8-week
interval, during which time the grafts have been exposed
to elevated flows and developed an endothelialized intima,
unilateral fistula ligation is performed. This results in a
70% reduction in blood flow rate through the affected
graft, leading to an increase in both smooth muscle cell
proliferation (SMC) and matrix deposition, with a corre-
sponding thickening of the intima.
To examine the potential for intimal atrophy and to
explore the underlying mechanisms that might be
involved in such a process, a “reverse flow switch” is
employed.2 Using a primate model, bilateral aortoiliac
grafts are placed without the initial augmentation in flow
created by a distal fistula. Following an 8-week interval, a
unilateral fistula is created, resulting in an acute threefold
increase in graft flow. The effect is a decrease in intimal
thickening, which occurs secondary to a reduction in SMC
proliferation, increase in SMC apoptosis, and a loss of pro-
teoglycan within the extracellular matrix.
Based on our observations in the rat carotid injury
model, we have identified platelet-derived growth factor
(PDGF) and nitric oxide (NO) as potential regulators of
flow-regulated prosthetic graft healing. 
Platelet-derived growth factor
The flow-dependent regulation of PDGF-A and PDGF-
B chain expression by endothelial cells in culture has been
well characterized. This response appears linked to the tem-
poral gradient of the shear, with abrupt changes in flow
being the most potent stimulus for increased gene expres-
sion. Using the flow-switch prosthetic graft model described
above, Northern blots prepared from grafts exposed to an
acute reduction in flow resulted in a 2.9-fold increase in
PDGF-A chain mRNA expression.3 In situ hybridization
confirmed this finding, demonstrating an increase in PDGF-
A expression in the intima of reduced flow grafts. PDGF-α
and -β receptor expression was also increased within the
graft intima (2.1- and 1.7-fold, respectively).
To further define the role of PDGF in intimal hyper-
plasia, a mouse/human chimeric anti–PDGF-β receptor
antibody was prepared. Initially using a primate balloon
injury model, inhibition of the PDGF-β receptor for 28
days following injury led to a significant reduction in inti-
mal area.4 This observation was expanded, using the flow-
switch model and anti–PDGF-α and -β receptor antibodies,
to investigation of the role of PDGF in flow-induced
remodeling.5 Similar to the balloon injury results, inhibi-
tion of the PDGF-β receptor led to a reduction in the flow-
mediated increase in intimal area. This was in contrast to the
effect seen with administration of the PDGF-α receptor
antibody, where a reduction in cell density within the intima
was observed without affecting intimal area. While PDGF-
A and –B chains are differentially regulated by flow and the
intracellular signaling pathways differ following binding to
the PDGF-α and -β receptors, the mechanisms that govern
these findings are not well defined.
Nitric oxide
Through experiments on the flow-dependent regula-
tion of arterial diameter, the influence of wall shear on
nitric oxide synthesis has been clearly demonstrated.
Recent in vitro data suggest that this flow-regulated pro-
duction of NO may directly control the changes in PDGF-
A chain expression described above. Experimental
evidence supports a role for NO in the response to injury
and vascular remodeling process in vivo. In our laboratory
we have confirmed this finding, demonstrating an increase
in injury-induced intimal thickening following administra-
tion of an inhibitor to NO production (Fischer and
Clowes, unpublished).
Our initial observation of an in vivo association
between wall shear and NO production was obtained
using the “reverse flow switch” prosthetic graft model
described above. Using this model, Northern blot analysis
of the intimas from grafts undergoing flow-mediated inti-
mal regression demonstrated a significant increase in
ecNOS expression.6 Immunohistochemistry confirmed
this increase in expression to be confined to the endothe-
lium. To investigate a potential cause and effect relation-
ship, inhibitors of NO were employed. Prosthetic grafts
were subjected to an acute increase in flow in the presence
of ecNOS blockade. Despite significant decreases in total
body NO production and platelet cGMP concentrations,
no change in flow-mediated intimal regression was
observed (Berceli and Clowes, unpublished). While these
experiments are an isolated observation occurring at 7
days following the increase in flow, they suggest that the
signaling mechanisms involved in flow-induced graft
remodeling are multifactorial.
Conclusion
Our laboratory has continued to investigate the sig-
naling mechanisms involved in development and regres-
sion of prosthetic graft intimal hyperplasia, as regulated by
the local hemodynamic environment. We built on our ini-
tial association between the development of intimal thick-
ening and an increase in PDGF and PDGF receptor
expression, demonstrating differing roles for the PDGF-α
and -β receptors during flow-induced remodeling of the
graft intima. Investigation of the intimal regression
process demonstrated an association between increased
NO production and loss of intimal area; however, further
attempts to clearly define the role of NO in our model
point to the complex and multifactorial mechanisms that
govern the graft healing process. 
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HEMODYNAMIC INFLUENCES ON
ANEURYSM DEVELOPMENT
Ronald L. Dalman, MD*
Abdominal aortic aneurysm (AAA) is a common and
potentially lethal disease with an estimated US incidence
of 20 to 40 cases/100,000 population/year. Most AAAs
are clinically silent until the time of rupture. Nearly
50,000 open AAA repair procedures are performed each
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year. Surgical mortality for elective AAA repair varies from
2% to 7%, but increases to 50% to 70% in urgent or emer-
gent circumstances. Risk factors for AAA development
include advancing age, male sex, chronic obstructive pul-
monary disease, cigarette smoking, hypertension and her-
itable predisposition.1
Inflammatory cell-mediated extracellular matrix
turnover is the likely cause of aortic aneurysmal degenera-
tion, expansion, and rupture in man. Characteristic patho-
logic changes include extensive medial and adventitial
elastin degradation, medial smooth muscle cell apoptosis,
and transmural macrophage, lymphocyte, dendritic and
plasma cell infiltration. AAA pathophysiologic inquiry to
date has been limited by an incomplete understanding of
the interplay between inflammation and hemodynamic
forces on aneurysm initiation and progression.
In the milieu of the “at risk” infrarenal aorta (as deter-
mined by genetic and environmental risks), characteristi-
cally “sedentary” flow conditions may facilitate aneurysmal
degeneration. Both chronic spinal cord injury patients
(Dalman, data on file) and major limb amputees2 develop
AAA at rates greater than otherwise comparable but nor-
mally ambulatory bipedal patients. Sedentary existence
increases oscillatory and low laminar shear stress (SS) con-
ditions in the infrarenal aorta. MR flow data obtained from
healthy subjects at rest and exercise demonstrate a dramatic
reduction in infrarenal aortic RFI (a measure of oscillatory
SS, defined as the time average of reverse flow/forward
flow × 100) with mild exercise.3 More strenuous exercise
completely eliminates the infrarenal aortic reverse flow
component (Taylor, data on file).
Complementary in vitro data from human umbilical
vein endothelial cultures (HUVEC) and bovine aortic
endothelial cultures (BAEVC) exposed to oscillatory and
laminar SS have suggested several potential mechanisms by
which steady, physiologic levels of laminar SS may offset or
diminish inflammation-mediated aneurysmal aortic
degeneration. Vascular endothelial cells sense and differ-
entially respond to varying SS patterns and intensities.
Suggested “laminar shear stress receptors” include mem-
brane ion channels (potassium, sodium, and chloride),
which have been demonstrated by blocking studies to reg-
ulate formation of nitric oxide (and NO synthase and
transforming growth factor β expression), and extracellu-
lar signal-regulated kinase (ERK-1) and ERK-2 endothe-
lial cell activation. Other putative SS receptors include
integrins (via focal adhesion site tyrosine kinases and
adapter proteins), cell-cell junction molecules such as
PECAM-1, caveolae (which contain serine/threonine and
tyrosine kinases and nitric oxide), and trimeric guanine
nucleotide-binding proteins, or G proteins (via Ras-
GTPase activity or ERK 1/2 activation).4
Following acute application of laminar shear stress to
cultured endothelial cells, ion channel activation and
downstream signal transduction pathways (receptor tyro-
sine phosphorylation, G-protein activation, and second
messenger mobilization) occur within seconds. Activation
of downstream signaling cascades such as MAP kinase
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pathways occurs within minutes, leading to SS responsive
gene transcription.5 To date, at least 40 such genes have
been identified, but differential display techniques suggest
that the ratio of shear-stress responsive mRNA to total
mRNA in in vitro cell conditions is 4%, leading to an esti-
mate of approximately 600 mammalian genes that may be
altered by 6-hour exposure to 15 dynes/cm2 shear stress.6
While providing significant insight into endothelial
mechanotransduction pathways, simple in vitro laminar
flow systems cannot fully replicate complex in vivo aortic
flow patterns. Cellular shear responses differentiate by
duration, intensity, and patterns of exposure. Several
genes are induced by laminar but not turbulent flow,
including Mn-superoxide dismutase, cyclooxygenase-2,
and BSC2.7 Changes in cyclic mechanical strain may also
influence relevant gene expression. The full range of
endothelial mechanotransductive responses remains to be
determined in relevant animal models or, ultimately, from
age- and risk factor–appropriate human aortic tissue
either ex vivo or in vivo.
Taken in aggregate, laminar flow induces potent anti-
adhesive, antioxidative, and anti-inflammatory gene
expression patterns. The expression of these genes may
ultimately mitigate or delay AAA initiation or enlargement,
providing the link between clinical observations of hemo-
dynamic risk factors and AAA pathophysiology. To deter-
mine the effect of increased aortic flow/decreased
peripheral resistance on in vivo aneurysmal enlargement,
we created distal arteriovenous fistulae (AVF) in a cohort
of male Sprague-Dawley rats 2 days after elastase infusion
in a 1-cm area of infrarenal aorta (E-AVF group), and com-
pared their aortic diameter on post-op day 14 with rats
who underwent elastase infusion alone (E-Sham), or
femoral AVF following vehicle infusion (V-AVF).8 The
elastase infusion (Anidjar Dobrin, or AD model) is the
most widely used and well-characterized animal AAA
model. Intraoperative fistula patency was confirmed via
demonstration of a more than twofold increase in femoral
arterial blood flow. Heart rate and mean arterial pressure
were monitored postoperatively. Prior to sacrifice, aortic
blood flow was measured, and the infused aortic segment
(AAA) and proximal noninfused infrarenal aortic segments.
Aortic diameter before and immediately after infusion
was comparable between groups. HR and MAP did not
vary within or between groups following infusion with
either elastase or vehicle. As measured immediately prior to
sacrifice, aortic flow in the fistula groups (V-AVF and E-
AVF) was double that of the E-Sham group (P < .017).
Typical flow-mediated aortic enlargement was present in
the proximal noninfused infrarenal aorta in the fistula
groups. However, the AAA diameter was significantly
smaller in the E-AVF than the E-S group (3.63 ± 1.63 mm
vs 5.29 ± 1.23 mm, P < .0167). Histologic examination
revealed characteristic medial and adventitial inflammatory
cell infiltration, medial disorganization, and adventitial
neovessel formation. This response appeared attenuated,
although not eliminated, in the presence of distal AVF. We
interpreted these data to suggest that increased flow/
decreased peripheral resistance following distal AVF cre-
ation mitigated against aneurysmal enlargement, despite
simultaneous, compensatory flow-mediated enlargement
in noninfused, noninflamed aortic segments.
We subsequently employed microarray expression
techniques (Affymetrix) to determine patterns of aortic
gene expression in response to increased flow. At 3, 7, 14,
and 21 days after AVF creation, total RNA was extracted
from harvested aortas and applied to a custom 805 gene
“rat chip.” This technique requires pooling two or three
samples per time point to achieve adequate RNA for
expression analysis. Expression patterns for intracellular
signaling molecules (such as connexin40) and cell-matrix
interface/shear transducers integrin A1 and B1 increase at
different rates. Connexin40 quickly rises then falls back to
quiescent levels, whereas the integrins trend upward
throughout the experiment. A total of 43 inflammation-
related genes were noted to have increased expression at
one or all time points, and 65 were downregulated.
Similar to the in vitro data, the aggregate effect of the
flow-mediated changes was antioxidative, antithrombotic,
anti-inflammatory, and antiproliferative. Copper/Zinc
superoxide dismutase, an antioxidant defense enzyme
whose level of expression adapts to changes in oxidative
stress, was the most highly differentially expressed gene
overall in post-AVF high-flow aortas.
Oxidative stress and production of reactive oxygen
species (ROS) may play a significant role in aneurysm
pathogenesis. In addition to direct tissue injury in chronic
inflammatory states, ROS activate the zymogen precursors
of many metalloproteinases previously linked to aneurysmal
degeneration. Even low-level ROS release increases the
expression of proinflammatory chemokines, cytokines, and
endothelial leukocyte adhesion molecules, thereby provid-
ing a positive feedback loop for perpetuation of the inflam-
matory response. ROS also rapidly inactivate antiproteases,
further tipping the balance of protease activity toward tissue
destruction. Within endothelial and vascular smooth muscle
cells, ROS act as second messengers via specific redox-
sensitive regulatory networks and signal transduction path-
ways to control gene expression and posttranslational pro-
tein modification. Redox-sensitive signaling pathways
include calcium ion signaling, protein phosphorylation (via 
both tyrosine kinase/phosphatases and serine/theronine
kinase/phosphatases), and ultimately, transcription factors
(particularly NF-κB and AP-l).9 HUVECs exposed to oscil-
latory shear produced a sustained increase NADH oxidase
activity and heme-oxygenase-1 (HO-1) versus static condi-
tions, while exposure to laminar shear produced only mild
transitory induction of HO-1 and NADH oxidase activity,
but progressively increased CuZn SOD mRNA through 24
hours of exposure.10
To confirm the potential significance of free-radical
reduction on inflammation-mediated aneurysmal enlarge-
ment, we recently treated a cohort of AD AAA rats with
α-tocopherol (vitamin E). Preliminary results suggest that
vitamin E is effective in reducing AAA enlargement in this
model. Whether this protective effect is due to diminished
inflammation (inflammatory-cell infiltration), the cytopro-
tective effects of free radical scavenging or an antioxidative
influence on cell signaling and protease activation remains
to be determined.
In summary, laminar SS may attenuate inflammation-
mediated aneurysmal degeneration through a variety of
complex mechanotransductive signaling pathways. One
promising example is cellular redox balance. Determination
of the initiation, propagation, and interplay between these
regulatory signaling pathways holds great promise for the
identification of effective inhibitor therapies for AAA.
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BIOMECHANICAL MODULATION OF ROS
AND TGF-β SIGNALING IN VASCULAR
SMOOTH MUSCLE CELLS
Phillip S. Tsao, PhD
It is now recognized that the vessel wall is an active tis-
sue that can dynamically respond to both biochemical and
biomechanical stimuli. Local alterations in these signals
cause the vessel to adapt to its surrounding milieu in what
has been described as vascular remodeling. This process
can result in a wide array of changes ranging from acute
vasomotor responses to alterations in the cellular and extra-
cellular matrix content of the vessel wall. Hemodynamic
forces impinging on the vessel wall may also play an impor-
tant role in determining the site and morphology of
atherosclerotic lesions. It has long been recognized that
the distribution of atherosclerotic lesions throughout the
vascular tree is nonuniform despite exposure to the same
hyperlipidemic and metabolically altered milieu. Pathologic
studies of human coronary arteries have revealed that ath-
erosclerosis tends to occur at bifurcations and other areas
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of flow disturbance in the coronary tree. These same
pathologic studies and, more recently, studies with IVUS
have also demonstrated that arteries often show compen-
satory outward remodeling at sites of atherosclerosis.1,2 As
atherosclerosis proceeds, the intimal layer thickens with the
accumulation of macrophage, smooth muscle cell, and
cholesterol. This intimal growth encroaches on the vascu-
lar lumen. As the lumen area decreases, the endothelial
shear stress rises. The endothelium then directs a program
of compensatory outward remodeling, which serves to
maintain flow rates and normalizes shear stress. 
The development of abdominal aortic aneurysms
(AAAs) may be an example of excessive outward vascular
remodeling. Alterations in local hemodynamic forces in
combination with a metabolically disturbed environment
can lead to an outward vascular remodeling process that
results in overcompensated enlargement of vessel size.
This outward remodeling process involves the degradation
of the extracellular matrix of the vessel wall by proteases
including MMP-2 and MMP-9. Aneurysm may result
from dysregulation of these proteases stimulated by ele-
vated cholesterol levels, inflammation, or oxidant stress.3
Although the precise roles of hemodynamic factors in the
pathogenesis of aneurysmal disease are not known, the
data demonstrating the importance of biomechanical fac-
tors in the initiation and progression of AAA are com-
pelling.4-6 Hypertension, which is known to result in
alterations in local hemodynamic forces in the aorta, has
been identified as an independent risk factor for aneurys-
mal disease. Furthermore, experimental alterations in the
hemodynamic environment can alter the morphology and
progression of aneurysms. 
It is now recognized that several hemodynamic forces
are transduced into biochemical signals by endothelial cells,
which can subsequently modulate the expression and activ-
ity of humoral mediators affecting vascular function.
Laminar shear stress, for example, stimulates acute produc-
tion of the potent vasodilator nitric oxide (NO).7
Moreover, shear stress increases expression of the gene
responsible for NO production, nitric oxide synthase
(NOS), via putative shear stress responsible elements in the
transcriptional promoter of NOS. Recent studies have indi-
cated a variety of genes are regulated by local shear forces
including vasoconstrictors (eg, endothelin-1) and vasodila-
tors (eg, NO and prostacyclin), as well as growth factors
(eg, TGF-β PDGF-a and -b). Additionally, shear stress
modulates the gene expression of endothelial adhesion
molecules and chemokines that mediate leukocyte-
endothelial cell interactions. Indeed, two important
endothelial regulators of monocyte adherence, vascular cell
adhesion molecule-1 (VCAM-1) and monocyte chemotac-
tic protein-1 (MCP-1) are negatively regulated by shear. 
The effect of another major biomechanical force,
cyclic strain, has also been investigated. Cyclical changes in
strain are imparted by the pressure waveform generated by
ventricular contraction. Intravascular pressure is transmit-
ted to the vessel wall by Laplace’s law and results in
mechanical stretch to vascular cells. The response of
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endothelial cells to cyclic strain appears to be distinct from
their response to shear stress. Endothelial cells and their
actin filaments align themselves parallel to the vector of
shear stress, but perpendicular to the vector of cyclic
strain. Studies of cyclic strain have demonstrated that
stretch induces expression of many of the same genes reg-
ulated by shear stress including endothelin-1, MCP-1, and
intracellular adhesion molecule-1 (ICAM-1), although
important differences in the expression pattern do exist.
For example, shear induces a transient increase in
endothelial MCP-1 expression that is followed by expres-
sion levels below baseline levels, whereas cyclic strain pro-
duces more prolonged expression.8 This difference may
underlie the opposing effects of shear stress and cyclic
strain on endothelial adhesiveness for monocytes and
lesion development.
Endothelial gene expression elicited by cyclic strain is
undoubtedly due to the transduction of these extracellular
signals to intracellular biochemical cascades. Although sev-
eral signaling molecules have been proposed to be affected
by biomechanical forces, we and others have focused on
the role of reactive oxygen species (ROS). Howard et al9
demonstrated in aortic endothelial cells that cyclic strain
induces activation of an enzymatic source of superoxide
anions and increased elaboration of H2O2. To investigate
the source of stretch-induced oxidative stress and the
mechanotransduction mechanisms involved, we plated
human aortic endothelial cells on flexible silicone strips
that were either uncoated or adsorbed with poly-L-lysine,
vitronectin, fibronectin, or collagen I. Cells were then
subjected to uniform sinusoidal stretch. Endothelial super-
oxide anion production was increased in cells exposed to
cyclic strain compared with static conditions. Further-
more, endothelial oxidative response to stretch was matrix
protein dependent whereby cells grown on fibronectin
and collagen I produced significantly more superoxide.
The oxidative response to cyclic strain was reduced by
coincubation with RGD peptides, blocking antibodies to
α2- and β1-integrins antibodies, as well as inhibitors of
protein kinase C. Studies utilizing various pharmacologi-
cal inhibitors indicated that the majority of superoxide
production stimulated by cyclic strain was due to an
NAD(P)H-dependent oxidase. Indeed, cyclic strain
induced an upregulation of the p22phox subunit as well as
the activity of this oxidase. To investigate the effect of
oxidative stress on gene transcription, endothelial cells
grown on collagen I were transfected with an NFκB-
sensitive luciferase construct. Cells that underwent cyclic
strain displayed a 10-fold induction of NFκB activation
compared with static controls. Strain-induced luciferase
activity was blunted by coincubation with RGD peptides,
calphostin C, or the NAD(P)H oxidase inhibitor,
diphenyliodonium. Thus, exposure of endothelial cells to
cyclic strain leads to integrin activation of a PKC-sensitive
NAD(P)H oxidase resulting in increased superoxide anion
production and mobilization of NFκB. 
Another important family of molecules that may be
important in the development of AAA is the TGF-β super-
family of growth factors. These protein growth factors
include the TGF-βs, Bone Morphogenic Proteins, and
Activins and are thought to have important roles in the
regulation of vascular cell growth and extracellular matrix
biology. The discovery of the Smad family of intracellular
signaling molecules specific to the TGF-β superfamily has
provided recent insight into the transcriptional effects of
these growth factors. Structure-function analysis of Smad
family members has led to their classification as signaling
Smads (Smad1,-2,-3,and -5), common partner Smad
(Smad4), and inhibitory Smads (Smad6 and -7). In the
case of TGF-β1, receptor activation leads to phosphoryla-
tion of a signaling Smad, Smad2. Subsequently, Smad2
associates with the common partner Smad, Smad4, in a
heteromeric complex, which then translocates to the
nucleus and influences the transcription of target genes.
Structurally similar to signaling Smads but lacking a phos-
phorylation domain, Smad6 and -7 are capable of com-
petitively inhibiting TGF-β signaling. It is interesting to
note that shear stress is known to increase the expression
of Smad6 and -7 in endothelial cells. Indeed, the discov-
ery of these two molecules was made during a gene dis-
covery program comparing endothelial cells exposed with
shear stress versus static conditions.10
Although a role for TGFβ has been implied in hyper-
tension-induced vasculopathy, little is known regarding
the effect of cyclic strain on TGF-β signaling. We demon-
strate that exposure of endothelial cells to physiological
levels of cyclic strain induces a slight increase in TGF-β
mRNA. This effect is associated with a reduction in Smad6
mRNA and protein, while no change is seen in Smad7.
This effect appears to be due to reduced stability of Smad6
mRNA after cyclic strain. Pretreatment with the antioxi-
dant n-acetylcysteine blocked the effect of cyclic strain on
Smad6 mRNA. Moreover, exposure of static endothelial
cells to exogenous H2O2 mimicked the effect of cyclic
strain. Since Smad6 is known to have important inhibitory
properties on TGF-β1 signaling, we investigated the
effects of cyclic strain on Smad activation. Western blot
analysis determined that reductions in Smad6 due to cyclic
strain were associated with increased phosphorylation 
of Smad2, with no change in total Smad2 levels. Fur-
thermore, cyclic strain resulted in increased activity of a
TGF-β sensitive promoter construct as well as a Gal4-
Smad2 fusion protein, indicating that Smad2-mediated
transcriptional activity was enhanced. These data demon-
strate a novel mechanism for regulation of Smad protein
signaling in endothelial cells and indicate that dysregula-
tion of Smad6 may have an important role in settings of
hypertension and inflammation.
In conclusion, biomechanical forces such as cyclic
strain can potently modulate vascular cell signaling and
gene expression. The local biomechanical milieu will,
therefore, influence the gene expression patterns at spe-
cific areas in the vascular tree under physiological as well
as pathophysiological conditions. Alterations in the
expression and activity of signaling molecules such as ROS
and Smad proteins induced by cyclic strain will undoubt-
edly have important implications into the mechanisms of
AAA development.
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MOLECULAR MEDIATORS OF ANEURYSMAL
DEGENERATION
Kirk A. Hance, MD
Scott J. Ziporin, MA
Robert W. Thompson, MD
Washington University School of Medicine
St Louis, Mo
Abdominal aortic aneurysms (AAAs) represent a chronic
degenerative disease of the aortic wall with life-threatening
implications. Over the past decade it has become clear that
several distinct but interrelated processes contribute to the
pathologic changes observed in human AAA tissue, includ-
ing chronic inflammation, elevated production of matrix
metalloproteinases (MMPs), and localized degradation of
connective tissue proteins. Recent efforts to identify the
molecular mediators of these processes have provided valu-
able insights into the pathophysiology of aneurysm disease,
as well as a basis for novel therapeutic strategies to suppress
aneurysmal degeneration.1
Mediators of chronic inflammation
Human and experimental AAAs are characterized by
inflammatory cell infiltrates that consist primarily of
mononuclear phagocytes and T-lymphocytes.2 While this
inflammatory response is qualitatively similar to that
occuring in occlusive atherosclerosis, the distribution of
inflammatory cells in AAAs occurs in a transmural fashion
with dense localized infiltrates concentrated within the
elastic media and adeventitia. Because the density of
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inflammatory cells within AAA tissue appears to correlate
with the extent of medial degeneration, this inflammatory
process is thought to be closely related to the connective
tissue destruction responsible for aneurysmal dilatation
and rupture. It therefore appears likely that the factors
regulating monocyte recruitment into the elastic media
and their retention within the outer aortic wall have an
important influence on the initiation and progression of
aneurysmal degeneration. 
At this point in time the cellular and molecular events
responsible for the initial recruitment of inflammatory
cells into the aortic media are unknown, but they may
include signals arising from hemodynamic stress upon
medial SMC, ischemia within the infrarenal aortic media,
autoimmune processes targeting elastic fiber components,
or simply an unusual extension of intimal atherosclerosis.
Once the process initiating aneurysm disease becomes
established, however, chemotactic peptides produced in
AAA tissue likely serve to amplify or accelerate the
mononuclear inflammatory response. Previous studies
have demonstrated increased expression of low molecular
weight chemokines in human AAA tissue, such as mono-
cyte chemoattractant protein-1 and interleukin-8.3 It has
also been suspected that biologically active products
released during matrix destruction, such as fragments of
elastin and laminin, might also play a unique role in the
inflammatory cell response that characterizes AAAs. 
In considering the latter possibility in more detail, we
have recently examined if the monocyte chemotactic activ-
ity elaborated by human AAA tissues is attributable to
interactions between elastin degradation peptides (EDPs)
and their cell surface receptor, the 67-kD elastin-binding
protein (EBP).4 In these experiments, soluble proteins
were extracted from human AAA tissues and chemotactic
activity for differentiated U937 mononuclear phagocytes
was measured in vitro, using a modified Boyden chamber,
and inhibition of chemotaxis was then tested by peptide
competition, blocking antibodies, and galactosugar-medi-
ated dissociation of the 67-kD EBP. Our results demon-
strate that AAA extracts stimulate a concentration-
dependent increase in monocyte migration that reaches up
to 24% of the maximal effect induced by N-formyl-Met-
Leu-Phe, and checkerboard analysis demonstrated that
AAA extracts stimulate monocyte chemotaxis without a
chemokinetic effect. AAA-derived chemotactic activity was
eliminated by competition with VGVAPG, a repetitive
peptide found in human elastin that binds to cellular
elastin receptors, and it was decreased nearly 40% in the
presence of BA-4, an antielastin monoclonal antibody 
that can block EDP-mediated chemotactic activity.
Furthermore, monocyte chemotaxis in response to both
VGVAPG and AAA extracts was abolished in the presence
of lactose, a galactosugar that specifically dissociates the
67-kD EBP, but it was unaffected by glucose, fructose, or
mannose. Because these findings indicate that soluble
EDPs released within human AAA tissue can subsequently
attract mononuclear phagocytes through ligand-receptor
interactions with the 67-kD EBP, the “EDP hypothesis”
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provides a plausible molecular mechanism to explain the
unique type of vascular inflammation that accompanies
aneurysmal degeneration. 
Mediators of connective tissue destruction
Mononuclear phagocytes are believed to mediate con-
nective tissue destruction in the outer aortic wall of AAAs,
in large part through their elaboration of matrix metallo-
proteinases (MMPs).5 The tissue environment of AAAs
includes elevated concentrations of inflammatory cytokines
capable of stimulating macrophage MMP expression, such
as tumor necrosis factor-α (TNFα) and interleukin-1β (IL-
1β). Direct cell-cell interactions may provide another
mechanism for amplifying local macrophage MMP pro-
duction; thus, activated T-lymphocytes bearing cell surface
CD40 ligand may interact with mononuclear phagocytes
that express CD40, an interaction known to dramatically
enhance macrophage production of MMPs.
To elucidate the specific role of individual MMPs in
aneurysmal degeneration, we have begun to utilize an
experimental model of AAAs induced by transient elastase
perfusion of the mouse aorta.6 Elastase-induced AAAs are
characterized by a progressive mononuclear inflammatory
response that is associated with elevated local expression of
MMPs and delayed degradation of medial elastin. As in
the analogous rat model, elastase-induced AAAs in the
mouse can be suppressed by treatment with doxycycline, a
tetracycline derivative with MMP-inhibiting properties. In
applying this model to mice with targeted deletion of
MMP-9, we found that MMP-9 deficiency is associated
with a consistent reduction in aneurysm development.
This “aneurysm-resistant phenotype” was associated with
preservation of the elastic lamellae despite the presence of
a mononuclear inflammatory response, suggesting that
MMP-9 plays a key role in mediating elastin degradation.
Further studies demonstrated that the aneurysm-resistant
phenotype of MMP-9–deficient mice can be “rescued” by
bone marrow transplantation from wild-type mice; more-
over, wild-type mice acquired the aneurysm-resistant phe-
notype by transplantation with MMP-9–deficient bone
marrow. While these experiments have demonstrated that
MMP-9 plays an essential role in the development of
experimental AAAs, parallel studies have revealed no dif-
ference in elastase-induced AAAs in mice lacking expres-
sion of MMP-12, another elastolytic MMP that has also
been implicated in aneurysm disease.6 Continuing applica-
tion of this model can be expected to reveal additional
insights into the specific molecular mechanisms of
aneurysmal degeneration.
In beginning to apply these experimental findings to
patients with AAAs, it is notable that increased production
of MMP-9 with AAA tissue may also be reflected by ele-
vated levels of MMP-9 in the circulation and that these
levels return to normal after surgical repair.7 This suggests
that plasma MMP-9 levels might serve as a useful “bio-
marker” of aneurysm disease; indeed, if further studies
support the hypothesis that plasma MMP-9 levels corre-
late with aneurysm expansion and with response to treat-
ment, this type of biomarker might be particularly useful
in characterizing and monitoring patients with small
asymptomatic AAAs. The use of doxycline has also
attracted great interest as a therapeutic strategy to achieve
inhibition of MMP-9 in patients with AAAs, and poten-
tially, to suppress the progression of aneurysm disease in
the clinical setting.8 A prospective, randomized clinical
trial to test this possibility is now under consideration.9
Summary
Descriptive studies on end-stage human aneurysm tis-
sues have previously documented pathologic relationships
between chronic inflammation, elevated expression of
matrix-degrading proteinases, and progressive connective
tissue destruction. Some of the molecular signals mediat-
ing these processes in AAAs have now been identified, and
better understanding of the role played by individual sig-
naling and effector molecules is beginning to emerge.
Although the temporal sequence of events underlying the
initiation and progression of aneurysmal degeneration has
been more difficult to ascertain, new experimental
approaches are rapidly helping to resolve some of these
questions, particularly through the combination of repre-
sentative experimental models with genetically-altered
mice. Important challenges for the future will be to under-
stand how the observed alterations in cellular and molec-
ular function correspond with changes in tissue
composition and with progressive aneurysm expansion,
and to continue the translation of this knowledge into
novel forms of therapy for clinical application.
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BASIC FIBROBLAST GROWTH FACTOR (FGF-2)
SIGNAL INTERRUPTION IN ARTERIAL INJURY
Michael A. Golden, MD
University of Pennsylvania School of Medicine 
Philadelphia, Pa
The normal artery is quiescent with very low prolifera-
tion levels and a stable structure. When injured, the artery
responds with a complex program that involves cellular
proliferation, cellular migration, and changes in extracellu-
lar matrix metabolism. These processes combine to result
in alteration of the arterial wall structure. Understanding
the regulation of vascular smooth muscle proliferation has
occupied a great deal of interest for us. Along with others,
we have used animal models to examine the regulation of
vascular smooth muscle proliferation in vivo. Much of the
work has been conducted in the rat carotid artery balloon
injury model. There is a sequence of events after arterial
injury, much of which is well defined; however, the signal-
ing that governs the events is not well understood. 
A number of studies have focused on the role of basic
fibroblast growth factor (FGF-2) in the artery wall
response to injury. In the resting state arterial wall cells
contain a large amount of FGF-2. There is also likely
growth factor resident in the extracellular matrix of the
arterial wall. Balloon injury of the arterial wall has been
shown to release a large amount of FGF-2 from preformed
stores, and this growth factor release affects the arterial
wall in terms of stimulating cellular proliferation and
migration.1 Others demonstrated that heparin administra-
tion, at the time of balloon arterial injury, binds and iso-
lates much of the released FGF-2 and thereby abrogates
much of its proliferative effect.2 We identified similar
results with a highly sulfated carbohydrate polymer in the
setting of balloon arterial injury. The polymer had a high
affinity for FGF-2 and significantly inhibited the arterial
wall response to balloon injury.3
However, looking past the initial burst of preformed
FGF-2 released by dead and damaged cells in the arterial
wall after balloon injury, leads to the question as to
whether or not a persistent effect of the growth factor is
involved in the arterial wall response to injury. Smooth
muscle cells, which occupy the arterial media are excellent
sources of FGF-2 and also express receptor that recognizes
the growth factor. It seems that ongoing FGF-2 expres-
sion and signaling play a role in the arterial response to
balloon injury. This was examined using an antisense strat-
egy to inhibit the ongoing synthesis of FGF-2 in the arte-
rial wall after balloon injury. An adenoviral construct
encoding an antisense sequence to FGF-2 was used to
evaluate this question and it revealed a significant role for
the continued expression of FGF-2. Gene transfer with the
antisense FGF-2 vector to inhibit synthesis of FGF-2 in
the setting of arterial balloon injury yielded a significant
inhibition of wall mass accumulation and also an increase
in apoptosis.4,5 The question of a role for FGF-2 signaling
was also approached by means of the receptor. Limiting
the signaling by manipulation of the receptor was also
approached with gene transfer techniques. This time an
adenoviral construct encoding a dominant negative
FGFR-1 receptor was used in the setting of arterial bal-
loon injury. This work also demonstrated an inhibitory
influence on the arterial wall response to balloon injury
with interference with FGF signaling in the arterial wall. 
We have also examined some of the same questions in
vivo in the setting of vein graft arterialization; another set-
ting where vessel wall smooth muscle cell response to per-
turbation can result in pathology.6 These studies have also
been instructive and support the concept that manipula-
tion of signaling molecules in the vessel wall can have great
influence on the vessel wall biology in response to physio-
logic challenge.
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SIGNAL TRANSDUCTION PATHWAYS AND
SMOOTH CELL REPLICATION
Michael A. Reidy
University of Washington
To understand the processes that are necessary for
smooth muscle cell (SMC) replication in vivo, we have
examined the signal transduction pathways that are acti-
vated in arteries, which have been subjected to balloon
catheter injury. Immediately after injury both the ERK and
PI3kinase cascades are activated with a small increase in
activity at later times. Interestingly, there is no increase in
activity after 7 days when the intimal SMCs are rapidly
dividing. To validate that these pathways participate in the
replication of medial SMC, we administered an MEK1
inhibitor to block the ERK1/2 cascade and wortmannin to
inhibit PI3K pathway. When given prior to injury, both
these inhibitors significantly reduced the early SMC repli-
cation (24-48 hours). PI3K inhibition also decreased cyclin
D1 expression. These results allow us to conclude that
both these pathways are necessary for SMC replication.
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The same MEK1 and PI3k inhibitors were adminis-
tered at day 5 after injury, but neither inhibitor decreased
intimal SMC replication. Surprisingly these cells show
strong expression of cyclin D1 and a high rate of SMC
replication. In an attempt to understand which signal
transduction pathways are active in the intima, we exam-
ined Ras and BMK1 activity and again found only back-
ground activity. The mechanism of how cyclin D1 is
induced in these intimal cells remains unknown. At later
times after injury (94 weeks), intimal SMC replicating
stops and the addition of growth factors cannot increase
the replication rate. To understand the cellular events that
maintain intimal SMC quiescent we examined activation
of signal transduction after the addition of FGF2 to ani-
mals with 4-week-old intimal lesions. Surprisingly, ERK
was activated, and an increase in cyclin D1 protein was
noted. However, there was no phosphorylation of RB and
no increase in cyclin A levels nor any increase in cdk2
activity. These cells, however, did show high levels of
p27Kip as well as p15INK4. Presumably, therefore, the
presence of these cell cycle inhibitors prevented SMC
replication. These results show that SMC utilize several
signal transduction pathways at different times during the
formation of intimal lesions. This presumably reflects the
fact that these cells are exposed to changing stimuli that
can either permit or block SMC replication.
EXPRESSION PROFILING PROVIDES CLUES
TO SMOOTH MUSCLE CELL FUNCTIONAL
DIVERSITY
Randolph L. Geary, MD
Lawrence D. Adams, PhD
James M. Wong, MD
Steven M. Schwartz, MD, PhD
Wake Forest University School of Medicine
Winston-Salem, NC
University of Washington
Seattle, Wash
Smooth muscle cells (SMC) comprise the bulk of the
artery wall and contribute to virtually all clinically impor-
tant arteriopathies. Excessive SMC growth leads to intimal
thickening, a key feature of atherosclerosis and the artery
wall response to mechanical injury. As the intima enlarges
a proportional loss of lumen caliber would occur if not for
a compensatory process of outward artery wall remodel-
ing.1,2 Failure of the artery wall to enlarge to accommo-
date intimal growth contributes to both stenosis and
restenosis and is due in part to SMC dysfunction. SMCs
also contribute to stability of advanced atherosclerotic
lesions by forming the fibrous cap that separates the
thrombogenic lipid core from flowing blood.3 Loss of cap
integrity precipitates thrombus formation and acute
ischemic syndromes. Optimal treatment or prevention of
these and other arterial diseases will require a better
understanding of the molecular basis of normal and patho-
logical SMC behavior.
To this end, we have begun a systematic analysis of
gene expression in normal and pathological SMC popula-
tions using DNA arrays.4 In our initial studies, normal
media from aorta and vena cava and pathological neoin-
tima from PTFE grafts were obtained from five nonhuman
primates (Macaca fascicularis). RNA was prepared and
radiolabeled probes were created and hybridized with
arrays containing sequences of 4048 known human genes.
This represents approximately one third of all named
human genes and a significant proportion of the total
expressed genome, estimated at 30,000 to 50,000 genes.
Adjacent vessel segments were fixed and embedded for
histology. Of the 4048 genes present on each filter,
approximately 3600 were expressed above background in
each tissue. Differential expression was then determined
by comparing hybridization intensities for each gene in the
three tissues from individual animals. Comparisons result-
ing in expression ratios of > 1.5-fold (±) in every animal
were defined as consistent. By these criteria only 68 genes
distinguished SMCs of aortic media from vena cava.
Surprisingly, all 68 were more highly expressed in aorta.4
Comparing SMCs of aortic media to graft neointima, 147
genes were consistently differentially expressed, 134
higher in aorta, and 13 higher in neointima.
When analyzing specific genes that met criteria for dif-
ferential expression between aortic media and vena cava
two known arterial markers were identified. These were
elastin (ratio, 5.0 ± 1.4, mean ± SEM) and APEG-1 (2.3 ±
0.6).4 Known neointimal markers were also identified in
comparison to aorta, including α2-procollagen-I (14.9 ±
1.2), osteoblast-specific factor-2 (5.8 ± 1.1), and versican
core protein (ratio, 4.8 ± 1.0).5 Many novel genes were
found that marked aorta from vena cava or neointima. Of
these, the most differential expressed marker of aortic
media was the regulator of G-protein signaling-5 (RGS5)
(45.6 ± 12.6 vs vena cava). RGS5 expression was interme-
diate in neointima with a ratio in aorta versus neointima of
11.6 ± 3.5. Array data were further validated using
Northern analysis and in situ hybridization. Probes for
RGS5,4 α2-procollagen-I,5 and versican core protein5 con-
firmed the array pattern for aorta, vena cava, and graft
neointima and localized expression to SMCs in each tissue. 
The gene that most clearly marked normal arterial
SMCs was RGS5, a member of a new family of approxi-
mately 25 proteins that inhibit G-protein signaling.6-8
When an agonist binds its G-protein–coupled receptor,
GDP is released from the Gα subunit in exchange for
GTP. Gα-GTP then dissociates from the Gβγ subunit.
Each can then bind one or more effector molecules to
stimulate or inhibit production of second messengers.
Signaling persists until Gα-GTP undergoes hydrolysis to
Gα-GDP and reassociates with the Gβγ subunit. All RGS
proteins contain one or more core RGS domain that acts
as a GTPase activating protein (GAP), binding to and
dephosphorylating Gα-GTP.8 In addition, variable length
C- and N-terminal sequences outside of the RGS domain
may function to regulate translocation to the plasma mem-
brane; selectivity among Gα subunits; and in some cases
provide independent effector activity.8
Most cells express a number of RGS proteins but little
is known about their pattern of expression or functions in
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the cardiovascular system. RGS4 has recently been studied
in transgenic mice where overexpression prevented cardiac
hypertrophy in response to pressure overload.9 RGS4
inhibits Gαq signaling and interestingly, a prior study in
transgenic mice found that Gαq overexpression caused
heart failure and hypertrophy.10 RGS5 is most closely
related to RGS48 and we have speculated that the high dif-
ferential expression in aorta versus vena cava may repre-
sent adaptation by SMCs to chronic hypertrophic stimuli
from arterial hemodynamic forces. To test this hypothesis,
we have initiated experiments to profile expression of
RGS5 and related genes in arterialized vein grafts. Further
insight into RGS5 function is being sought by comparing
expression in atherosclerosis-prone and atherosclerosis-
resistant arteries and in specific artery wall pathologies
including the fibrous cap, constrictive remodeling, and
intimal hyperplasia following angioplasty. 
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G-PROTEINS AND INTIMAL HYPERPLASIA
Mark G. Davies, MD, PhD
University of Rochester
Rochester, NY
Cells respond to extracellular signals by transmitting
intracellular instructions to coordinate appropriate re-
sponses. Signal transduction pathways employ protein
phosphorylation and protein dephosphorylation to trans-
mit this information through the different cellular com-
partments in order to elicit physiological responses. The
balance between the activities of specific protein kinases
and protein phosphatases modulates the extent of protein
phosphorylation in vivo. It is well accepted that extracel-
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lular ligands trigger nuclear signals through a cascade of
protein-protein interactions. There are two basic ligand
operated receptor mechanisms responsible for signal trans-
duction: firstly, ligand-modulated release of a secondary
intracellular mediator (G-protein coupled receptors) and
secondly, ligand-regulated enzyme activity (tyrosine kinase
coupled receptors). Targeting signal transduction path-
ways is a novel avenue for molecular therapeutics. There
are over 1000 G-protein–coupled receptors (GPCR).
Four hundred of these are considered nonsensory GPCRs.
Forty-one are targets of commercial drugs, and 48 are tar-
geted for drug development. 
G-proteins classification and action
G-proteins are intrinsic membrane-bound proteins
that act as transmembrane signal transducers in cells; they
consist of three distinct subunits: α, β, and γ; βγ forms a
tightly associated dimer. G-protein heterotrimers are clas-
sified according to differences in their Gα subunits. Their
activation is intimately associated with receptor activa-
tion. Receptor-G-protein activity is regulated tightly by a
series of G-protein related kinases, which dephosphory-
late the receptor and a second family of proteins, regula-
tors of G-protein signaling (RGS), which regulate the
GTP activity of the heterotrimeric units. Thereafter,
downstream secondary mediator activation is regulated
by the process of receptor internalization, which involves
the key proteins dynein, β-arrestin, and caveolin. In gen-
eral, Gαi protein subtypes (αi1, αi2, and αi3), act to
inhibit adenylate cyclase and to decrease intracellular
cAMP levels (Kaziro, 1991 #531; Taussig, 1993 #533).
The two Gαs proteins (45kDa and 52kDa forms) can
both mediate the activation of adenylate cyclase with an
increase in intracellular cAMP and can also regulate cal-
cium channels. Gαq subunits have been shown to activate
phospholipase Cβ. The traditional role of the Gβγ sub-
units, released following activation of the Gαi proteins, is
to bind to the active αs-GTP species, thus reducing their
activity and leading to decreased cAMP levels. Gβ sub-
units, of which seven isoforms are now identified, can
stimulate several phospholipases and either activate or
inactivate adenylate cyclase isoforms. Gγ subunits, of
which four isoforms are now identified, appear to act in
concert with the Gβ subunits. Gβγ subunits of the per-
tussis toxin sensitive Gαi proteins can enhance the effect
of Gαs on type II and IV adenylate cyclase but can inhibit
Gαs-stimulated type I adenylate cyclase. The other three
Gαs-stimulated adenylate cyclases (type III, V, and VI)
appear not to be modulated by the Gβγ subunits. βγ
Subunits have also been shown to activate phospholipase
C isozymes (PLC- β, γ, and δ). 
G-proteins and proliferation
The role of G-protein signal transduction in the cellu-
lar proliferation is being defined. In mesenchymal cells,
Gαi G-proteins mediate enhancement of ERK activity,
DNA synthesis, and cell proliferation. Furthermore, a
Gαi-regulated role in mitosis has been identified in fibro-
blast cell lines. In BALB/c3T3 cells, Gαi2 and Gβγ are
responsible for ERK activation and DNA synthesis, while
Gαi3 is responsible for cell transformation. Gβγ subunit
activation results in proliferation through the activation of
common receptor tyrosine kinase pathways, involving
Gβγ-mediated activation of Src-like kinases to activate
Shc-Grb2-Sos pathways. This leads to activation of p21ras
(ras) and subsequent activation of the ERK1/2 cascade.
Ras, once activated, can activate raf directly or act on
PI3Kinase to induce raf, protein kinase B (akt), and rac
phosphorylation. Gβγ-mediated ERK activation has
recently been shown to involve transactivation of the epi-
dermal growth factor receptor.
G-proteins and migration
The role of G-protein signal transduction in the cellu-
lar migration is less well defined. However, G-proteins are
likely to play a significant role, as evidence in other systems
of G-protein–coupled receptor involvement in migration.
Migration of inflammatory cells is driven in part by fami-
lies of chemokines, whose receptors are G-protein coupled
and pertussis toxin sensitive. The presence of pertussis
toxin sensitivity suggests the association of Gαi. Further
data have demonstrated a role for ras, rac, rho, and
ERK1/2 in chemokine-linked Gαi-induced cascades. It
appears that receptors coupled to Gαi can mediate chemo-
taxis, even when they lack the distinguishing features of
chemokine receptors and when their agonist ligands are
not classical chemokines. Activation of Gαi is required but
probably not sufficient for chemotaxis. Although Gαi cou-
pled receptors undergo internalization during many cell
induced responses such as mitogenesis, similar Gαi recep-
tors can mediate chemotaxis without undergoing agonist-
induced internalization. Irrespective of the Gαi, Gβγ is an
essential mediator of chemotaxis. Integrin signaling in
cells is mediated through FAK but is also associated with
an integrin-associated protein, which is G-protein coupled
and pertussis toxin sensitive. Thrombin will induce migra-
tion that is pertussis toxin sensitive. PDGF and IGF both
have pertussis toxin sensitive elements in migration assay,
when they are used as chemoattractants. In the case of
IGF, Gβγ can be coimmunoprecipitated with the IGF
receptor and in the case of thrombin, there is transactiva-
tion of epidermal growth factor receptor by Gβγ. 
G-protein expression and response to injury
We have determined the changes in G-protein expres-
sion (Gαi and Gβγ subunits) and function that occur in
veins following grafting after 28 days in non cholesterol
fed rabbits and compared these results with control jugu-
lar veins from the same animals. There was elevated
expression of Gαi2 and Gβγ subunits, no expression of
Gαi1 and Gαo subunits, and de novo expression of Gαi3
occurring in vein grafts. Northern blotting showed a
twofold increase in expression of mRNA for Gαi3 and
Gαi2 in the vein grafts compared with the jugular veins at
28 days. This altered G-protein subunit expression was
associated with a change in the functional coupling of
serotonergic receptors to G-proteins with the vein grafts
developing pertussis toxin (PTx) sensitive responses, while
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the control jugular veins have a pertussis toxin insensitive
response. The time course of G-protein expression in
experimental vein grafts harvested postoperatively was also
determined and demonstrated that changes in the expres-
sion of G-proteins in the vein grafts, particularly the Gαi3
and Gβγ subunits, paralleled the formation of intimal
hyperplasia. We have verified these findings in the rat
carotid injury model and have demonstrated that a similar
pattern of change occurs during the development of inti-
mal hyperplasia. These results suggest that the smooth
muscle cell phenotype involved in the intimal hyperplasia
response undergoes changes in membrane transducing
systems with the expression of new components and
changes in the coupling of these components to surface
receptors. We have attempted to investigate the effect of
flow on G-protein expression. Using a coculture system,
our group has shown that elevation in flow alone will
increase the expression Gαi3 in endothelial cells without
significant increases in Gαi2, Gαq, and Gαs. In contrast,
there was an endothelium-dependent decrease in Gαi2
expression in the smooth muscle cells. There was no effect
on the expression of Gαi3, Gαq, and Gαs. Receptor G-
protein coupling as measured by agonist stimulated
GTPase and adenylate cyclase activity was markedly
increased by the introduction of high flow. 
Given the changes in G-proteins, modulating G-pro-
teins expression or function should affect the intimal
hyperplastic response in vein grafts. The role of Gβγ sig-
naling was examined by targeting a gene encoding a spe-
cific Gβγ inhibitor, the carboxyl terminus of the
β-adrenergic receptor kinase (βARKCT), which contains a
Gβγ binding domain. Two strategies were employed to
control βARKCT function. The βARKCT was delivered by
plasmid or adenovirus. Vein graft intimal hyperplasia was
significantly reduced by 37%, and the normal alterations in
G protein-coupling in this model after grafting (ie, devel-
opment of PTx sensitivity) were blocked by βARKCT treat-
ment. Concomitantly, Koch et al confirmed that βARKCT
will inhibit intimal hyperplasia in the rat model and we
have recently demonstrated that pertussis toxin, a Gαi
inhibitor, will also reduce intimal hyperplasia in vivo. Thus,
Gαi/Gβγ-mediated pathways appear to play a major role in
intimal hyperplasia development. Further work on defining
the roles of the respective GRKs and RGS is ongoing.
G-proteins represent a significant, little-explored signal
transduction system in the development of vascular disease.
Targeting G-proteins coupled responses, instead of individ-
ual receptors, appears to offer a novel therapeutic strategy. 
PROTEOMICS
Ron Orlando
University of Georgia
Athens, Ga
There has been a revolution in biology since the intro-
duction of the polymerase chain reaction in the mid
1980s. This revolution has until recently focused on the
sequencing of genes, and has led to the large-scale
genome sequencing projects that are in progress. This
emphasis on straight sequencing has, in turn, given rise to
a second focus on functional genomics, epitomized by the
use of cDNA microarray technology, in an attempt to
understand how the information contained in the
genomic sequence of an organism is used, and to bridge
the gap between raw sequence data and the state of the
proteins within an organism. Unfortunately, there is an
increasing realization that often very poor correlations
exist between the level of any particular mRNA and the
protein it is encoding. This may be due to a number of
reasons, including posttranslational processing and widely
varying turnover rates. 
One response to this problem by the biochemical
community has been the development of the field of pro-
teomics. Proteome was defined in 1996 as the “total pro-
tein complement of the genome.” Proteomics has become
an area of study centering on the identification and char-
acterization of the total expression of proteins in cells, tis-
sues, and organisms and the factors causing this to change.
Understanding complex biological systems, their interac-
tions with and reactions to various stimuli, is the ultimate
goal of many researchers. 
The typical procedure for viewing protein expression
patterns is two-dimensional (2-D) gel electrophoresis.
This enables much of the proteome to be displayed using
both molecular weight and isoelectric point to resolve
individual proteins, and provides the relative abundance of
the proteins observed. 
Mass spectrometry (MS) has emerged as the most
common method for unequivocally identifying proteins in
2-D gels. In this process, the identity of proteins in 2-D
gels is obtained by excising the protein spots of interest,
and washing/destaining the gel plugs. This is followed by
cleaving the protein backbone with an endoprotease
(trypsin being the most common) and eluting the resultant
peptides from the gel plug. An aliquot of this sample
is then analyzed by matrix-assisted laser desorption/
ionization (MALDI) mass spectrometry, which provides
the masses of the proteolytic peptides. This mass spectro-
metric peptide “map” or “fingerprint” of the protein is
queried against a nonredundant sequence database con-
taining lists of proteolytic peptides predicted from the
amino acid sequences of all known protein sequences.
Proteins in the database query are scored and ranked by the
number of matching peptide masses, mass accuracy, and
protein size/pI obtained from the 2-D gel experiment.
Some samples cannot, however, be identified by the
peptide masses determined by MALDI MS. This situation
may occur if the number of peptide masses is too low for a
specific database query, if the gel piece contains a mixture
of proteins, or if the protein being analyzed contains post-
translational modifications. The other possibility is, of
course, that the protein is novel and the sequence is not
present in the database. In these instances, the remaining
portion of the sample is subjected to tandem mass spec-
trometry (MS/MS). This procedure provides a partial
amino acid sequence from several of the peptides present in
the sample. In MS/MS the sample is ionized, and the first
mass spectrometer provides separation based upon the
mass-to-charge ratio (m/z) of the primary ions. An ion at a
single m/z value is then selected and passed into a collision
chamber between the two mass spectrometers where it is
fragmented by collision with an inert target gas. The frag-
ment ions are then detected after passing through the sec-
ond mass spectrometer where they are analyzed based
upon their m/z values. This process produces a series of
fragment ions that differ by single amino acids, thus allow-
ing at least a portion of the peptide’s sequence to be deter-
mined. The portion of the peptide’s amino acid sequence
determined by MS/MS can be used to query against the
sequence databases. In this procedure, the peptide mass
and partial sequence are combined into what is commonly
called “a Peptide Sequence Tag.”1,2 This combination of
information results in a search with a very high specificity.
Unique hits in the database can be obtained with only
three to four amino acids being identified.1,2 When a pep-
tide has been identified, the theoretical fragmentation is
predicted and compared with the MS/MS spectrum for
assignment of other peaks that can validate the identifica-
tion. This procedure can be repeated for every fragmented
peptide in the sample and leads to additional verification of
the result or identification of other proteins in the sample. 
Proteins that are not identified by the two identifica-
tion procedures discussed above are deemed as novel. The
first step in identifying and characterizing the biological
function of such a protein is to obtain amino acid
sequences that can be used for cloning the protein. The
information from the MS/MS experiments is used to
search EST and genome databases. In the event that one
or several nucleotide sequences can be identified, long
sequences are obtained for primer construction. If this is
not the case, the initial MS/MS experiments will typically
provide approximately 50% of the amino acid sequence
from the protein, which can be used to generate primers. 
Identification is only the first step in understanding the
biological role of a protein. Increasingly protein modifica-
tions, which occur both during and after its expression, are
implicated in its function. The type and number of post-
translational modifications cannot be easily predicted from
the DNA sequence alone and requires analysis at the pro-
tein level. The identification and characterization of post-
translational modifications is clearly where the field of
proteomics is headed and will keep scientists in this area
busy for years to come.
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Vascular injury results from the activation of particular
cell types in response to atheromatous deposits, normal
and abnormal shear forces, trauma, or aneurysmal degen-
eration. These events initiate independent but overlapping
signal transduction cascades that ultimately culminate 
in alterations in cell physiology in an attempt to restore
vascular homeostasis. Work from many laboratories over
the last 15 years has revealed that signaling events in
eukaryotic cells involve the reversible assembly of large
multiprotein complexes. These multicomponent signaling
“machines” integrate and transmit information to control
ion fluxes, cytoskeletal rearrangements, patterns of gene
expression, cell cycle progression, and programmed cell
death. What holds these “signalosomes” together at the
molecular level, and what cellular events control the tim-
ing and location of their assembly? Some answers to these
questions have emerged from investigations into the mod-
ular nature of the signaling proteins themselves. 
At the structural level, many proteins involved in sig-
nal transduction are found to consist of discrete domains
or modules, each with a relatively well defined function,
assembled together in a combinatorial fashion. Scattered
between these domains, and occasionally within them, are
short linear sequence motifs that are targeted by these
types of modular domains for phosphorylation and/or
binding. For example, members of the Src tyrosine kinase
family involved in platelet activation contain a protein
tyrosine kinase domain, an Src-Homology 2 (SH2)
domain, and an Src-Homology 3 (SH3) domain. The
kinase domain phosphorylates tyrosine residues if they are
surrounded by the correct sequence of amino acids, while
the SH2 domain binds to motifs containing phosphory-
lated tyrosine residues and the SH3 domain binds to pro-
line-rich sequences. In the inactive form of Src, the SH2
and SH3 domains are tied up in intramolecular associa-
tions, while upon activation, these domains independently
help to recruit Src to its correct location and facilitate its
interaction with its substrates. 
In a general sense, the combination of modular
domains and short sequence motifs present within signal-
ing proteins provides a theoretical basis for the organiza-
tion of sequential signaling cascades. For example, a kinase
domain on protein X might phosphorylate protein Y to
generate a binding site in Y for an SH2 domain in protein
Z. When Z now binds to Y, a kinase domain in Y can
phosphorylate a new site in Z, permitting Z to now inter-
act with further downstream effector molecules. In this
manner, interactions between separate domains in signal-
ing proteins function as a sort of “molecular Lego” to
form large multicomponent complexes. The coupling of
stoichiometric binding via short motif sequences along
with catalytic activation through covalent protein modifi-
cations allows both high fidelity and amplification in the
signaling process. Despite the complexity of the human
genome, the number of discrete intracellular modular sig-
naling domains seems to be rather small, probably num-
bering less than 200 in total. The optimal amino acid
sequence motifs recognized by a number of these signal-
ing modules, or phosphorylated by certain tyrosine, serine
and threonine kinases have already been determined,
though a large number still remain unidentified. 
What do we know about the motifs that these domains
bind to? In the broadest general terms, modular signaling
domains can be roughly divided into those that bind to
sequences that are constitutively present within their li-
gands, and those domains that bind to sequence motifs
that arise only when the respective ligands have been phos-
phorylated on Tyr, Ser or Thr residues. 
Constitutive sequences recognized by modular signal-
ing domains often contain one or more repeats of the
amino acid proline. SH3 domains typically recognize the
core sequence PxxP, where x denotes a variety of other
amino acids depending upon the particular SH3 domain.
In addition, one or more basic residues (R or K) often
reside three positions N-terminal to the first P
(R/KxxPxxP; so-called mode I binding) or two positions
C-terminal to the second P (PxxPxR/K; so-called mode II
binding). WW domains also bind to proline-rich stretches
within proteins, typically recognizing such sequences as
PPxY, PPLP and PPR, or RPP. EVH1 domains bind to the
sequence E/DFPPPP, while EH domains recognize NPF
motifs. Finally, a subset of PTB domains bind to NPXY
and related motifs within their ligands. A number of pro-
teins containing SH3, EVH1, and WW associate directly
or indirectly with the actin cytoskeleton and play critical
roles in signaling pathways that control cell shape and
motility. The binding affinities of these domains for their
constitutive sequences, however, are relatively weak, (Kds
in the range of 5-100 µmol/L) suggesting that these types
of interactions alone are probably insufficient for the for-
mation of stable signaling complexes. PDZ domains con-
stitute another protein module that binds to short
sequence motifs constitutively present within their targets.
Many PDZ domains, though not all, recognize the
extreme C-terminal 3-5 amino acids of their ligands.
Furthermore, PDZ domain–containing proteins usually
contain multiple PDZ domains in addition to other sig-
naling modules. PDZ domain–containing molecules are
thought to play critical roles in organizing multiprotein
complexes at the plasma membrane. For example, in
polarized epithelia, different PDZ domain proteins local-
ize to different membrane compartments, (ie, the basal or
apical surface of the cell), where they serve to cluster a vari-
ety of transmembrane receptors, channels, and cytosolic-
signaling proteins into active complexes.
The second broad group of signaling modules requires
that the ligands possess a particular phosphorylated amino
acid in order for the domain to bind. Because these inter-
actions usually involve ionic bonds between the phospho-
amino acid’s phosphate group and particular amino acid
side chains in the binding module, they provide both high
affinity (Kds in the nM range) and a means to regulate pro-
tein-protein assembly through phosphorylation/dephos-
phorylation, much like turning a light switch on and off.
The best characterized modules in this class bind to phos-
photyrosine-based sequence motifs. When cells are
exposed to PDGF, a growth factor involved in intimal
hyperplasia, for example, the PDGF receptor undergoes
autophosphorylation on at least five different tyrosine
residues. Following phosphorylation, each of the phospho-
tyrosine residues provides a binding site for different SH2
domain-containing proteins, resulting in the recruitment
of PLC-γ, PI-3 kinase, Src, SHP2, and RasGAP into acti-
vated receptor complexes. The specificity of different SH2
domains for phosphotyrosine-containing motifs comes
from the amino acid sequence surrounding the phosphoty-
rosine. In addition to binding the phosphotyrosine, most
SH2 domains select for a particular sequence of amino
acids lying within three or five positions C-terminal to the
pTyr. Knowledge of the optimal sequence motif recog-
nized by a particular SH2 domain allows one to predict
whether two proteins are likely to bind to each other
through an SH2-mediated interaction. In addition to SH2
domains and the large number of proteins that contain
them, a subset of PTB domains also bind to phosphotyro-
sine-containing motifs. PTB domains generally recognize
the sequence NPXpY, (pY denotes phosphotyrosine). PTB
domain–containing proteins often contain other modular
binding domains such as SH2, SH3, and WW domains,
allowing them to serve as scaffolds for the assembly of sig-
naling complexes at particular locations within the cell,
such as adjacent to the plasma membrane or in a complex
with cell surface receptors. 
Tyrosine phosphorylation is an early event seen in all
cells following growth factor stimulation, and for many
years it was thought that protein-protein interactions reg-
ulated by protein phosphorylation were unique to phos-
photyrosine. In contrast, phosphorylation of proteins on
serine and threonine residues was thought to regulate pro-
tein function largely through allosteric modifications
rather than by directly mediating protein-protein interac-
tions. Within the last few years, however, a variety of sig-
naling molecules and modular domains have been
identified that specifically bind short phosphoserine/thre-
onine-containing motifs, recruiting these substrates into
protein-protein signaling complexes in response to phos-
phorylation by Ser/Thr kinases. The best known example
of this involves a very abundant protein present within all
eucaryotic cells, known as 14-3-3. 14-3-3 proteins have
been found to bind to over 50 different phosphorylated
proteins in the cell, including Raf, a MAP kinase regulator
involved in cell differentiation and proliferation; Cdc25, a
phosphatase that controls the cell cycle in response to
injury; and BAD, a protein involved in the initiation of
apoptosis. The phosphoSer/Thr sequence motif that 14-
3-3 protein’s recognize is very similar to the sequence
motifs phosphorylated by protein kinases such as PKA,
PKC, and AKT, allowing some of the substrates of these
kinases to bind to 14-3-3 following phosphorylation. In
some cases 14-3-3 binding exerts a direct effect on protein
function, but in the majority of cases, binding of these
proteins to 14-3-3 seems to control where in the cell the
bound cargo resides. 
More recently, several other modular signaling
domains have been identified that also bind to phosphor-
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ylated Ser or Thr residues. A small subset of WW
domains has been identified that recognize the sequence
pSer/Thr-Pro. Remarkably, this motif matches the
sequence that results from phosphorylation of proteins
by MAP kinases such as Erk, JNK, and p38, suggesting
that these kinases may target some of their substrates for
WW domain-binding. Another modular signaling
domain, known as an FHA domain, also binds to pThr-
containing sequence motifs. FHA domains are found in
a variety of proteins involved in pathways that regulate
the response of cells to DNA damage, as well as within
proteins involved in gene transcription and intracellular
transport, and it seems likely that FHA domains function
much like SH2 domains to regulate protein-protein
interactions in response to phosphorylation. Two other
potential phosphoserine/threonine–binding modules
deserve mention: WD40 repeats and leucine rich regions
(LRRs). Although proof that these modules directly bind
to pSer/Thr motifs is not as complete as that for 14-3-3
proteins, WW domains, and FHA domains, the circum-
stantial evidence that they participate in the binding of
phosphorylated protein substrates is compelling.
Polypeptides containing WD40 repeats and LRRs are
often found as subunits within protein machines that tar-
get substrates for proteosomal degradation by ubiquiti-
nation. Thus, these pSer/Thr-interacting modules
probably play key roles in controlling the abundance of a
particular protein within the cell, allowing protein levels
to be regulated by the action of particular protein kinases
on their substrates. One example of this phenomenon is
cell signaling mediated by the NFκB pathway. Following
the activation of IκB kinase, the WD40 containing pro-
tein βTrCP, binds to phosphorylated IκB and targets it
for ubiquitin-mediated degradation. This releases NFκB
from its inactive cytoplasmic IκB-bound form and allows
NFκB to enter the nucleus and drive the expression of a
particular set of target genes. 
Why should we spend so much time studying the
details of signaling modules? A detailed molecular under-
standing of how these modules function, particularly at
the atomic level, provides the foundation for rational drug
design aimed at inhibiting a specific signaling pathway in a
predictable way. In theory, at least, this approach should
provide us with precision drugs that accomplish a thera-
peutic goal with a minimum of unwanted side effects—a
pharmacological scalpel, in a sense. The second reason lies
in our ability to obtain the greatest medical benefits from
the human genome sequencing effort. The complete
determination of the human genome now presents us with
the great challenge of “decoding” this information in the
human “proteome” and then gleaning from that raw pro-
tein sequence data some new concepts of cell, tissue, and
organ physiology in health and disease. By combining the
ability to recognize modular signaling domains within
these proteins, with a detailed knowledge of the individual
sequence motifs that these modules recognize, we can
begin to organize signaling pathways in silico using bioin-
formatics. Computer-based biology is likely to become
more and more prominent in the next decade, as bioin-
formatics begins to guide experimental design. Vascular
biologists in the 21st century will need to be as comfort-
able with their computers and test tubes as their predeces-
sors were with scalpels and suture.
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PROTEIN TRANSDUCTION: DELIVERY OF
BIOLOGICALLY ACTIVE PROTEINS IN VIVO
Steven F. Dowdy, PhD
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Delivery of therapeutic peptides and proteins into tis-
sues and across the blood:brain barrier is severely limited by
size and biochemical properties. To solve the delivery prob-
lem, we further developed the ability to transduce interme-
diate (1000-5000 d) and large molecules (> 5000 d) into
cells by coupling them to the 11 residue protein transduc-
tion domain (PTD) embedded in the HIV TAT protein.1-3
TAT-fusions rapidly transduce into 100% of all cell types in
a concentration-dependent fashion reminiscent of passive
diffuse, regardless of size or structure. Indeed, compounds,
peptides, antisense oligonucleotides, metal ions, and full-
length proteins have been transduced into cells. Using this
strategy, we have delivered peptides and full length, biolog-
ically active proteins in excess of 100,000 d into most, if not
all, cells in mouse models. These observations suggest that
in vivo protein transduction or “Protein Therapy” has the
potential to develop entirely new therapies to treat human
disease. Recently, we have been focusing our efforts on
reconstitution of tumor suppressor protein function in
tumors in vivo by local and systemic delivery of TAT-ARF,
TAT-p53, and TAT-p27 proteins.
REFERENCES
1. Schwarze, et al. Protein transduction: unrestricted delivery into all
cells? Trends Cell Biol 2000;10:290-5.
2. Schwarze, et al. In vivo protein transduction: delivery of biologically
active protein into the mouse. Science 1999;285:1569-72.
3. Lissy, et al. A common E2F1 and p73 pathway mediates cell death
induced by TCR-activation. Nature 2000;407:642-5. 
